TREATMENT READING
Childhood Non-Hodgkin Lymphoma
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
85 sections
- Response to therapy
- Treatment Option Overview for Childhood NHL
- Medical Emergencies
- Mediastinal masses
- Tumor lysis syndrome
- Tumor Surveillance
- Special Considerations for the Treatment of Children With Cancer
- Standard treatment options for Burkitt lymphoma
- Treatment options for recurrent or refractory Burkitt lymphoma
- Treatment options under clinical evaluation for Burkitt lymphoma
- Treatment options for diffuse large B-cell lymphoma
- Treatment options for recurrent or refractory diffuse large B-cell lymphoma
- Treatment options under clinical evaluation for diffuse large B-cell lymphoma
- Treatment options for primary mediastinal B-cell lymphoma
- Chemotherapy and rituximab
- Radiation therapy
- Treatment options for recurrent or refractory primary mediastinal B-cell lymphoma
- Treatment options under clinical evaluation for primary mediastinal B-cell lymphoma
- Standard Treatment Options for Lymphoblastic Lymphoma
- Treatment Options for Recurrent or Refractory Lymphoblastic Lymphoma
- Treatment Options Under Clinical Evaluation for Lymphoblastic Lymphoma
- Standard Treatment Options for Anaplastic Large Cell Lymphoma
- Treatment Options for Recurrent or Refractory Anaplastic Large Cell Lymphoma
- Treatment Options Under Clinical Evaluation for Anaplastic Large Cell Lymphoma
- Treatment options for lymphoproliferative disease associated with primary immunodeficiency
- Treatment options for NHL associated with DNA repair defect syndromes
- Treatment options for HIV-associated NHL
- Treatment options for PTLD
- Treatment options under clinical evaluation for PTLD
- Immunodeficiency Associated With Acute Lymphoblastic Leukemia (ALL) Therapy
- Treatment options for pediatric-type follicular lymphoma
- Treatment options for marginal zone lymphoma (including MALT lymphoma)
- Treatment options for primary CNS lymphoma
- Treatment options for peripheral T-cell lymphoma
- Treatment options for cutaneous T-cell lymphoma
- Treatment options for mycosis fungoides
- Treatment options for lymphomatoid papulosis
- Certain factors affect prognosis (chance of recovery) and treatment options.
- Sometimes childhood non-Hodgkin lymphoma does not respond to treatment or recurs (comes back) after treatment.
- Treatment Option Overview
- Key Points
- There are different types of treatment for children with non-Hodgkin lymphoma.
- Children with non-Hodgkin lymphoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.
- The following types of treatment may be used:
- Surgery
- Chemotherapy
- Radiation therapy
- Stem cell transplant
- Targeted therapy
- Other drug therapy
- Phototherapy
- Watchful waiting
- Immunotherapy
- Treatment for childhood non-Hodgkin lymphoma may cause side effects.
- Patients may want to think about taking part in a clinical trial.
- Follow-up care may be needed.
- Treatment Options for Childhood Non-Hodgkin Lymphoma
- Burkitt lymphoma
- Treatment of Burkitt lymphoma
- Treatment of recurrent or refractory Burkitt lymphoma
- Diffuse large B-cell lymphoma
- Treatment of diffuse large B-cell lymphoma
- Treatment of recurrent or refractory diffuse large B-cell lymphoma
- Primary Mediastinal B-cell Lymphoma
- Treatment of primary mediastinal B-cell lymphoma
- Treatment of recurrent or refractory primary mediastinal B-cell lymphoma
- Lymphoblastic Lymphoma
- Treatment of lymphoblastic lymphoma
- Treatment of recurrent or refractory lymphoblastic lymphoma
- Anaplastic Large Cell Lymphoma
- Treatment of anaplastic large cell lymphoma
- Treatment of recurrent or refractory anaplastic large cell lymphoma
- Lymphoproliferative Disease Associated With Immunodeficiency in Children
- Treatment of lymphoproliferative disease associated with primary immunodeficiency
- Treatment of non-Hodgkin lymphoma associated with DNA repair defect syndromes
- Treatment of HIV-associated non-Hodgkin lymphoma
- Treatment of post-transplant lymphoproliferative disease
- Rare NHL Occurring in Children
- Treatment of pediatric-type follicular lymphoma
- Treatment of marginal zone lymphoma
- Treatment of primary CNS lymphoma
- Treatment of peripheral T-cell lymphoma
- Treatment of cutaneous T-cell lymphoma
- Treatment of mycosis fungoides
- Treatment of lymphomatoid papulosis
Response to therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Regardless of histology, pediatric patients with NHL that is refractory to first-line therapy have a very poor prognosis,[19-23] with the exception of patients with anaplastic large cell lymphoma.[19,24] As opposed to other hematologic malignancies, it has been difficult to demonstrate the prognostic value of early response to therapy in pediatric NHL.
Burkitt lymphoma: Historically, response to the initial prophase treatment was considered an important predictive factor. Poor responders (i.e., <20% resolution of disease) had an event-free survival (EFS) rate of 30%.[25,26] However, poor response to initial treatment was not found to be an adverse prognostic factor in the Inter B-NHL Ritux 2010 (NCT01516580) trial, in which patients were treated with more effective therapy.[27]
Sources: 25 · 26 · Inter B-NHL Ritux 2010 (NCT01516580) · 27
Lymphoblastic lymphoma: The presence of a residual mediastinal mass at day 33 or at the end of induction was not found to be associated with decreased survival in the BFM 90-95 studies. However, all patients with less than 70% reduction at the end of induction had therapy intensified.[28]
Sources: 28
International pediatric NHL response criteria have been proposed but require prospective evaluation. The clinical utility of these new criteria are under investigation.[29]
Sources: 29
In contrast to the prognostic value of minimal residual disease (MRD) in patients with acute leukemia, the prognostic value of MRD after therapy is initiated remains uncertain and requires further investigation in pediatric patients with NHL.
Burkitt lymphoma: One study suggested an inferior outcome for patients with Burkitt lymphoma who had detectable MRD after induction chemotherapy.[30] However, other studies found that detectable MRD at the end of induction was not prognostic, possibly because of the low number of relapses in patients with disease detected in the blood or bone marrow at diagnosis.[31,32]
Anaplastic large cell lymphoma: A retrospective analysis of a collaborative European study showed that after induction, MRD-negative patients had a relapse risk of approximately 20% and an overall survival (OS) rate of approximately 90%. By contrast, MRD-positive patients had a relapse risk of 81% and an OS rate of 65% (P < .001). The presence of MRD is significantly associated with uncommon histological subtypes containing small cell and/or lymphohistiocytic components.[33][Level of evidence B4]
Sources: 33 · Level of evidence B4
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Treatment Option Overview for Childhood NHL
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Many of the advancements in childhood cancer survival have been made by using combinations of known and/or new agents to improve the best available, accepted therapy. Clinical trials in pediatrics are designed to compare potentially better therapy with currently accepted standard therapy. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new treatment and comparing the results with those previously obtained with standard therapy.
All children with non-Hodgkin lymphoma (NHL) should consider enrolling in a clinical trial. Treatment planning by a multidisciplinary team of cancer specialists with experience treating tumors of childhood is strongly recommended to determine, coordinate, and implement treatment to achieve optimal survival. Children with NHL should be referred for treatment by a multidisciplinary team of pediatric oncologists at an institution with experience in treating pediatric cancers. Information about ongoing National Cancer Institute (NCI)–supported clinical trials is available from the NCI website.
Sources: NCI website
NHL in children is generally considered to be widely disseminated at diagnosis, even when the tumor is apparently localized. As a result, combination chemotherapy is recommended for most patients.[1] Exceptions to this treatment strategy include the following:
Sources: 1
Peripheral T-cell lymphoma that is limited to the skin, including anaplastic large cell lymphoma.
Sources: Peripheral T-cell lymphoma that is limited to the skin, including anaplastic large cell lymphoma
Indolent mature B-cell lymphomas.
Pediatric-type follicular lymphoma.
Sources: Pediatric-type follicular lymphoma
Posttransplant lymphoproliferative disease (when immunosuppression can be safely decreased).
In contrast to the treatment of adults with NHL, the use of radiation therapy is limited in children with NHL. Study results include the following:
Early studies demonstrated that the routine use of radiation had no benefit for patients with low-stage (I or II) NHL.[2]
Sources: 2
Studies have demonstrated that prophylactic central nervous system (CNS) radiation can be omitted in patients with pediatric NHL.[3-6]
For patients with anaplastic large cell lymphoma and B-cell NHL who present with CNS disease, radiation can also be eliminated.[5,6]
Radiation therapy may have a role in treating patients who have not had a complete response to chemotherapy. Data to support limiting the use of radiation therapy in the treatment of pediatric NHL come from the Childhood Cancer Survivor Study.[7] This analysis demonstrated that radiation exposure was a significant risk factor for subsequent neoplasms and death in long-term survivors.
Sources: 7
The treatment of NHL in childhood and adolescence has historically been based on the histological subtype of the disease. A study by the Children’s Cancer Group demonstrated that the outcomes for patients with lymphoblastic lymphoma were superior with longer acute lymphoblastic leukemia–like therapy, while patients with nonlymphoblastic NHL (Burkitt lymphoma) had superior outcomes with short, intensive, pulsed therapy. The outcomes for patients with large cell lymphoma were similar with either approach.[8]
Sources: 8
Outcomes for children and adolescents with recurrent NHL remain very poor, with the exception of patients with anaplastic large cell lymphoma.[9-14] Patients or families who desire additional disease-directed therapy should consider entering trials of novel therapeutic approaches. Regardless of whether a decision is made to pursue disease-directed therapy at the time of progression, palliative care remains a central focus of management. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to terminal illness.
Table 3 describes the treatment options for newly diagnosed and recurrent childhood NHL.
Sources: Table 3
| Treatment Group | Treatment Options | ||
|---|---|---|---|
| CAR = chimeric antigen receptor; CNS = central nervous system; EBV = Epstein-Barr virus; HSCT = hematopoietic stem cell transplant; MALT = mucosa-associated lymphoid tissue; PTLD = posttransplant lymphoproliferative disease. | |||
| Mature B-cell NHL: | |||
| Burkitt lymphoma | Newly diagnosed | Surgery (for stage I and II only) | |
| Chemotherapy with or without rituximab | |||
| Recurrent or refractory | Chemotherapy with or without rituximab | ||
| Allogeneic or autologous HSCT | |||
| CAR T-cell therapy | |||
| Bispecific antibody therapy | |||
| Diffuse large B-cell lymphoma | Newly diagnosed | Surgery (for stage I and II only) | |
| Chemotherapy with or without rituximab | |||
| Recurrent or refractory | Chemotherapy with or without rituximab | ||
| Allogeneic or autologous HSCT | |||
| CAR T-cell therapy | |||
| Primary mediastinal B-cell lymphoma | Chemotherapy and rituximab | ||
| Radiation therapy | |||
| Lymphoblastic lymphoma | Newly diagnosed | Chemotherapy | |
| Cranial radiation therapy for overt CNS disease only | |||
| Recurrent or refractory | Nelarabine or nelarabine-containing chemotherapy regimens | ||
| Chemotherapy | |||
| Bortezomib with chemotherapy | |||
| Allogeneic HSCT | |||
| Anaplastic large cell lymphoma | Newly diagnosed | Surgery followed by chemotherapy (for stage I) | |
| Chemotherapy | |||
| Recurrent or refractory | Chemotherapy, brentuximab, and/or ALK inhibitors (e.g., crizotinib or alectinib) | ||
| Allogeneic or autologous HSCT | |||
| Lymphoproliferative disease associated with immunodeficiency: | |||
| Lymphoproliferative disease associated with primary immunodeficiency | Chemotherapy with or without rituximab | ||
| Allogeneic HSCT | |||
| NHL associated with DNA repair defect syndromes | Chemotherapy | ||
| HIV-associated NHL | Chemotherapy with or without rituximab | ||
| PTLD | Surgery and reduction of immunosuppressive therapy, if possible | ||
| Rituximab alone | |||
| Standard or slightly modified chemotherapy with or without rituximab | |||
| Low-dose chemotherapy with or without rituximab | |||
| Rare NHL: | |||
| Pediatric-type follicular lymphoma | Surgery only | ||
| Chemotherapy with or without rituximab | |||
| Marginal zone lymphoma | Surgery only | ||
| Radiation therapy | |||
| Rituximab with or without chemotherapy | |||
| Antibiotic therapy, for MALT lymphoma | |||
| Primary CNS lymphoma | Chemotherapy and rituximab | ||
| Radiation therapy | |||
| Peripheral T-cell lymphoma | Chemotherapy | ||
| Radiation therapy | |||
| Allogeneic or autologous HSCT | |||
| Cutaneous T-cell lymphoma | No standard treatments have been established | ||
| Mycosis fungoides | No standard treatments have been established | ||
| Lymphomatoid papulosis | No standard treatments have been established | ||
Sources: Surgery · Chemotherapy with or without rituximab · Chemotherapy with or without rituximab · Allogeneic or autologous HSCT · CAR T-cell therapy · Bispecific antibody therapy · Surgery · Chemotherapy with or without rituximab · Chemotherapy with or without rituximab · Allogeneic or autologous HSCT · CAR T-cell therapy · Chemotherapy and rituximab · Radiation therapy · Chemotherapy · Cranial radiation therapy for overt CNS disease only · Nelarabine or nelarabine-containing chemotherapy regimens · Chemotherapy · Bortezomib with chemotherapy · Allogeneic HSCT · Surgery followed by chemotherapy · Chemotherapy · Chemotherapy, brentuximab, and/or ALK inhibitors (e.g., crizotinib or alectinib) · Allogeneic or autologous HSCT · Chemotherapy with or without rituximab · Allogeneic HSCT · Chemotherapy · Chemotherapy with or without rituximab · Surgery and reduction of immunosuppressive therapy, if possible · Rituximab alone · Standard or slightly modified chemotherapy with or without rituximab · Low-dose chemotherapy with or without rituximab · Surgery only · Chemotherapy with or without rituximab · Surgery only · Radiation therapy · Rituximab with or without chemotherapy · Antibiotic therapy, for MALT lymphoma · Chemotherapy and rituximab · Radiation therapy · Chemotherapy · Radiation therapy · Allogeneic or autologous HSCT · No standard treatments have been established · No standard treatments have been established · No standard treatments have been established
Medical Emergencies
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The most common potentially life-threatening clinical situations, seen in patients with lymphoblastic lymphoma and Burkitt lymphoma, are the following:
Mediastinal masses.
Sources: Mediastinal masses
Tumor lysis syndrome.
Sources: Tumor lysis syndrome
Mediastinal masses
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Patients with large mediastinal masses are at risk of tracheal compression, superior vena caval compression, large pleural and pericardial effusions, and right and left ventricular outflow compression. Thus, cardiac or respiratory arrest is a significant risk, particularly if the patient is placed in a supine position for procedures such as computed tomography (CT) or echocardiography scans.[15] Most of these procedures can be performed with patients on their side or prone.
Sources: 15
Because of the risk of complications from general anesthesia or heavy sedation, a careful physiological and radiographic evaluation of the patient should be completed, and the least invasive procedure should be used to establish the diagnosis of lymphoma.[16,17] The following procedures may be used:
Bone marrow aspirate and biopsy.
Thoracentesis. If a pleural or pericardial effusion is present, a cytological diagnosis is frequently possible using thoracentesis, with confirmation of the diagnosis and cell lineage by flow cytometry.
Lymph node biopsy. In children who present with peripheral adenopathy, a lymph node biopsy performed under local anesthesia and with the patient in an upright position may be possible.[18]
Sources: 18
In situations when the above procedures do not yield a diagnosis, the use of a CT-guided core-needle biopsy should be considered. This procedure can frequently be performed using light sedation and local anesthesia before more invasive procedures are undertaken. Care should be taken to keep patients out of a supine position. Mediastinoscopy, anterior mediastinotomy, or thoracoscopy are the procedures of choice when other diagnostic modalities fail to establish the diagnosis. A formal thoracotomy is rarely, if ever, indicated for the diagnosis or treatment of childhood lymphoma.
Occasionally, it will not be possible to perform a diagnostic operative procedure because of the risk of complications from general anesthesia or heavy sedation. In these situations, preoperative treatment with steroids or, less commonly, localized radiation therapy should be considered. Because preoperative treatment may affect the ability to obtain an accurate tissue diagnosis, a diagnostic biopsy should be done as soon as the risk of complications from general anesthesia or heavy sedation is reduced.
Tumor lysis syndrome
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Tumor lysis syndrome results from rapid breakdown of malignant cells, causing several metabolic abnormalities, most notably hyperuricemia, hyperkalemia, and hyperphosphatemia. Patients may present with tumor lysis syndrome before the start of therapy.
Hyperhydration and allopurinol or rasburicase (urate oxidase) are essential components of therapy in all patients, except those with the most limited disease.[19-24] In patients with G6PD deficiency, rasburicase may cause hemolysis or methemoglobinuria and should be avoided. An initial prephase consisting of low-dose cyclophosphamide and vincristine does not obviate the need for allopurinol or rasburicase and hydration.
Hyperuricemia and tumor lysis syndrome, particularly when associated with ureteral obstruction, frequently result in life-threatening complications.
Tumor Surveillance
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Although the use of positron emission tomography (PET) to assess rapidity of response to therapy appears to have prognostic value in Hodgkin lymphoma and some types of NHL observed in adult patients, it remains under investigation in pediatric NHL. To date, there are insufficient data for pediatric NHL to support a finding that early response to therapy assessed by PET has prognostic value.
Diagnosing relapsed disease solely based on imaging requires caution because false-positive results are common.[25-28] Data also demonstrate that PET scanning can produce false-negative results.[29] A study of young adults with primary mediastinal B-cell lymphoma demonstrated that 9 of 12 patients who had residual mediastinal masses at the end of therapy had positive PET scans. Seven of these nine patients had the masses resected, but no viable tumor was found.[30] Before changes in therapy are undertaken based on residual masses noted by imaging, even if the PET scan is positive, a biopsy to prove residual disease is warranted.[28]
Special Considerations for the Treatment of Children With Cancer
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Transplant surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Standard treatment options for Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The treatment of Burkitt lymphoma is the same as treatment for diffuse large B-cell lymphoma, and the following discussion is pertinent to both types of childhood NHL.
Unlike mature B-lineage NHL seen in adult patients, there is no difference in outcome based on histology in pediatric patients (Burkitt lymphoma or diffuse large B-cell lymphoma). Pediatric Burkitt lymphoma and diffuse large B-cell lymphoma are clinically very aggressive, and patients are treated with very intensive regimens.[21-26]
Tumor lysis syndrome is often present at diagnosis or after initiation of treatment. This emergent clinical situation should be anticipated and addressed before treatment is started. For more information, see the Tumor lysis syndrome section.
Sources: Tumor lysis syndrome
Current treatment strategies are based on risk stratification, as described in Table 4. Involvement of the bone marrow may lead to confusion about whether the patient has lymphoma or leukemia. Traditionally, patients with more than 25% marrow blasts are classified as having mature B-cell leukemia, and those with fewer than 25% marrow blasts are classified as having lymphoma. It is not clear whether these arbitrary definitions are biologically distinct, but there is no question that patients with leukemic involvement should be treated with protocols designed for Burkitt lymphoma.[21,23,26]
| Stratum | Disease Manifestation | |
|---|---|---|
| ALL = acute lymphoblastic leukemia; BFM = Berlin-Frankfurt-Münster; CNS= central nervous system; FAB = French-American-British; LDH = lactate dehydrogenase; LMB = Lymphome Malin de Burkitt; NHL = non-Hodgkin lymphoma. | ||
| aBased on results of the FAB/LMB-96 study, a serum LDH level more than twice the upper limit of normal has been used to define a group B high-risk group in the international B-cell NHL study ANHL1131 (NCT01516567).[22] | ||
| COG-C5961 (FAB/LMB-96);[22,23,27]COG-ANHL1131 (Inter-B-NHL Ritux 2010) [26] | A | Completely resected stage I and abdominal stage II |
| Ba | Multiple extra-abdominal sites | |
| Nonresected stage I and II, III, IV (marrow <25% blasts, no CNS disease); epidural masses (stage III Murphy staging) are treated as group B unless there is evidence of dural invasion | ||
| C | Mature B-cell ALL (>25% blasts in marrow) and/or CNS disease | |
| BFM Group [28] | R1 | Completely resected stage I and abdominal stage II |
| R2 | Nonresected stage I or II and stage III with LDH <500 IU/L | |
| R3 | Stage III with LDH 500–999 IU/L | |
| Stage IV, B-ALL (>25% blasts), no CNS disease, and LDH <1,000 IU/L | ||
| R4 | Stage III, IV, B-cell ALL with LDH >1,000 IU/L | |
| Any CNS disease | ||
Sources: ANHL1131 (NCT01516567) · 22 · 22 · 23 · 27 · 26 · 28
The following studies have contributed to the development of current treatment regimens for pediatric patients with Burkitt lymphoma and diffuse large B-cell lymphoma.
Evidence (chemotherapy):
Berlin-Frankfurt-Münster (BFM) studies
Berlin-Frankfurt-Münster (BFM) studies
Localized disease (R1 and R2 groups): The BFM group has treated risk group R1 patients with two cycles of multiagent chemotherapy (GER-GPOH-NHL-BFM-90 and GER-GPOH-NHL-BFM-95).[21,28] R2 patients received a cytoreductive phase followed by five cycles of chemotherapy.[21,28]
Berlin-Frankfurt-Münster (BFM) studies › Localized disease (R1 and R2 groups): The BFM group has treated risk group R1 patients with two cycles of multiagent chemotherapy (GER-GPOH-NHL-BFM-90 and GER-GPOH-NHL-BFM-95).[21,28] R2 patients received a cytoreductive phase followed by five cycles of chemotherapy.[21,28]
Event-free survival (EFS) rates with best therapy in the NHL-BFM-95 study were higher than 95% for R1 and R2 group patients.[21]
Sources: 21
Berlin-Frankfurt-Münster (BFM) studies
Advanced/disseminated disease (R3 and R4 groups): In the NHL-BFM-95 study, the EFS rate was 93% with best therapy.[21]
Sources: 21
Berlin-Frankfurt-Münster (BFM) studies › Advanced/disseminated disease (R3 and R4 groups): In the NHL-BFM-95 study, the EFS rate was 93% with best therapy.[21]
Inferior outcome was observed for patients with CNS disease at presentation (3-year EFS rate, 70%).[28]
Sources: 28
French Society of Pediatric Oncology Lymphome Malin de Burkitt (LMB) and French-American British (FAB) studies
French Society of Pediatric Oncology Lymphome Malin de Burkitt (LMB) and French-American British (FAB) studies
Localized disease (group A): Patients who received two cycles of multiagent chemotherapy, without intrathecal chemotherapy or rituximab, had excellent outcomes (COG-C5961 [FAB/LMB-96]).[27][Level of evidence B4]
Sources: COG-C5961 [FAB/LMB-96] · 27 · Level of evidence B4
Advanced disease (group B):
French Society of Pediatric Oncology Lymphome Malin de Burkitt (LMB) and French-American British (FAB) studies › Advanced disease (group B):
The 3-year EFS rate was 90% for stage III patients and 86% for stage IV (CNS-negative and nonleukemic) patients.
Patients with a lactate dehydrogenase (LDH) level more than twice the upper limit of normal had an EFS rate of 86% compared with 96% in those with lower LDH levels.
French Society of Pediatric Oncology Lymphome Malin de Burkitt (LMB) and French-American British (FAB) studies
Disseminated disease (group C):
French Society of Pediatric Oncology Lymphome Malin de Burkitt (LMB) and French-American British (FAB) studies › Disseminated disease (group C):
Patients with leukemic disease only, and no CNS disease, had a 3-year EFS rate of 90%, while patients with CNS disease at presentation had a 3-year EFS rate of 70%.
Patients with combined marrow and CNS disease at diagnosis had an EFS rate of only 61%.
This study identified the response to prophase reduction as the most significant prognostic factor. Patients with poorly responding disease (i.e., <20% resolution of disease) had an EFS rate of 30%.
Both the BFM and FAB/LMB studies demonstrated that omission of craniospinal irradiation, even in patients presenting with CNS disease, does not affect outcome (COG-C5961 [FAB/LMB-96] and NHL-BFM-90 [GER-GPOH-NHL-BFM-90]).[21-23,28]
Sources: COG-C5961 [FAB/LMB-96] · 21 · 23 · 28
Evidence (rituximab):
In a phase II study performed by the BFM group, single-agent rituximab showed activity in pediatric patients with Burkitt lymphoma.[29][Level of evidence B4]
Sources: 29 · Level of evidence B4
A Children's Oncology Group (COG) pilot study (COG-ANHL01P1) added rituximab to baseline chemotherapy with FAB/LMB-96 therapy in patients with stage III and stage IV B-cell NHL.[30-32]; [24][Level of evidence C1]
Sources: COG-ANHL01P1 · FAB/LMB-96 · 30 · 32 · 24 · Level of evidence C1
A Children's Oncology Group (COG) pilot study (COG-ANHL01P1) added rituximab to baseline chemotherapy with FAB/LMB-96 therapy in patients with stage III and stage IV B-cell NHL.[30-32]; [24][Level of evidence C1]
Compared with chemotherapy-only protocols, toxicity was similar with the addition of rituximab, despite a trend toward higher peak levels of rituximab in younger patients.
An international randomized phase III trial (COG-ANHL1131) evaluated the benefit of adding rituximab to standard therapy for Group B patients with high levels of LDH and Group C patients. The study was closed early because of the superior outcomes observed for the patients who received rituximab.[26] This study led to the European Medicines Agency and U.S. Food and Drug Administration approval of rituximab for the treatment of pediatric patients with B-cell lymphoma.
Sources: 26
An international randomized phase III trial (COG-ANHL1131) evaluated the benefit of adding rituximab to standard therapy for Group B patients with high levels of LDH and Group C patients. The study was closed early because of the superior outcomes observed for the patients who received rituximab.[26] This study led to the European Medicines Agency and U.S. Food and Drug Administration approval of rituximab for the treatment of pediatric patients with B-cell lymphoma.
For patients in the rituximab arm, the EFS rate was 94% for this high-risk group of patients (stage III with elevated LDH and stage IV), compared with 82% for patients who received standard therapy (hazard ratio, 0.32; 95% confidence interval [CI], 0.15–0.66; one-sided P = .00096).
Refractory disease or relapse/progression was observed in 15% of patients who received standard therapy, compared with 3% of patients who received rituximab.
Toxic mortality occurred in 2% of patients in each arm.
For patients who received rituximab, there was no difference in outcome based on age, histology (diffuse large B-cell lymphoma vs. Burkitt lymphoma), stage, and response to low-dose cyclophosphamide, vincristine, and prednisone (COP regimen).
A prespecified, secondary aim of the study was to evaluate the immune effects of rituximab therapy in pediatric patients after the completion of intensive therapy.[33] Patients in the rituximab group were significantly more likely to have low IgG, IgA, and IgM serum concentrations 1 month after the end of therapy than patients in the chemotherapy-only group. Low IgG levels persisted for 1 year after the start of therapy for patients who received rituximab. No fatal infections were observed in the follow-up period. However, a small number of patients who had all received rituximab had severe infections.
Sources: 33
Standard treatment options for Burkitt lymphoma and diffuse large B-cell lymphoma are described in Table 5.
Sources: Table 5
| Trial | Stratum | Disease Manifestations | Treatment |
|---|---|---|---|
| ALL = acute lymphoblastic leukemia; BFM = Berlin-Frankfurt-Münster; CNS = central nervous system; COG = Children's Oncology Group; FAB = French-American-British; LDH = lactate dehydrogenase; LMB = Lymphome Malin de Burkitt; NHL = non-Hodgkin lymphoma; POG = Pediatric Oncology Group. | |||
| COG-C5961 (FAB/LMB-96) [22,27] COG-ANHL01 [31,32]; [24][Level of evidence C1] COG-ANHL1131 (Inter-B-NHL Ritux 2010) [26] | A | Completely resected stage I and abdominal stage II | Two cycles of chemotherapy [27] |
| B | Multiple extra-abdominal sites | Prephase + four cycles of chemotherapy (reduced-intensity arm) [22,34] | |
| Nonresected stage I and II, III (normal LDH) | |||
| Stage III (elevated LDH), marrow <25% blasts, no stage IV CNS disease | Prephase + four cycles of chemotherapy (reduced-intensity arm) + six doses of rituximab [26] | ||
| C | Mature B-cell ALL (>25% blasts in marrow) and/or stage IV CNS disease | Prephase + six cycles of chemotherapy (full-intensity arm) and only two maintenance cycles + six doses of rituximab [26] | |
| GER-GPOH-NHL-BFM-95 [21] | R1 | Completely resected stage I and abdominal stage II | Two cycles of chemotherapy |
| R2 | Nonresected stage I/II and stage III with LDH <500 IU/L | Prephase + four cycles of chemotherapy (4-hour methotrexate infusion) | |
Sources: COG-C5961 · 22 · 27 · 31 · 32 · 24 · Level of evidence C1 · 26 · 27 · 22 · 34 · 26 · 26 · 21
Treatment options for recurrent or refractory Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
There is no standard treatment option for patients with recurrent or progressive disease. For patients with recurrent or refractory aggressive mature B-cell NHL, survival rates range between 10% and 50%. In the largest series, the survival rate was about 20%.[23,35,36]; [37][Level of evidence C1] Three large retrospective multivariable analyses identified the following prognostic factors:
Sources: 23 · 35 · 36 · 37 · Level of evidence C1
For improved survival:
One site of disease at relapse.[38]
Sources: 38
No failure in bone marrow.[39]
Sources: 39
Diffuse large B-cell lymphoma histology.[38]
Sources: 38
Complete remission before hematopoietic stem cell transplant (HSCT).[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
Reinduction with intensive continuous therapy before HSCT.[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
For inferior survival:
For inferior survival:
Progression during initial therapy.[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
Rituximab during initial therapy.[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
Treatment options for recurrent or refractory Burkitt lymphoma and diffuse large B-cell lymphoma include the following:
R-ICE regimen (rituximab plus ifosfamide, carboplatin, and etoposide [ICE]).[40]
Sources: 40
CYVE regimen (high-dose cytarabine and etoposide) for relapsed group A and group B disease.[38]
Sources: 38
Bispecific antibody (anti-CD20, anti-CD3) therapy.[44]
Sources: 44
Chimeric antigen receptor (CAR) T-cell therapy.[45]
Sources: 45
R-VICI regimen (rituximab, vincristine, idarubicin, ifosfamide, carboplatin, and dexamethasone).[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
Chemoresistance makes remission difficult to achieve.
Evidence (treatment of recurrent or refractory Burkitt lymphoma):
A study from the United Kingdom for children with relapsed or refractory mature B-cell NHL and B-cell acute lymphoblastic leukemia reported the following:[46]
Sources: 46
A study from the United Kingdom for children with relapsed or refractory mature B-cell NHL and B-cell acute lymphoblastic leukemia reported the following:[46]
The most favorable outcomes occurred in patients who received rituximab and an autologous HSCT.
However, the study could not distinguish whether this relationship reflected that children who survived were those who remained well enough to tolerate chemotherapy and rituximab, achieved a response, and were eligible for transplant.
In a COG study of 20 patients with relapsed/refractory B-cell NHL (Burkitt lymphoma [n = 14] and diffuse large B-cell lymphoma) who were treated with R-ICE, the following was observed:[40][Level of evidence C1]
Sources: 40 · Level of evidence C1
In a COG study of 20 patients with relapsed/refractory B-cell NHL (Burkitt lymphoma [n = 14] and diffuse large B-cell lymphoma) who were treated with R-ICE, the following was observed:[40][Level of evidence C1]
A complete remission/partial remission rate of 60%.
The Japanese Pediatric Leukemia/Lymphoma Study Group performed a phase II study using R-ICE to treat 28 pediatric patients with relapsed/refractory B-cell NHL.[47]
Sources: 47
The Japanese Pediatric Leukemia/Lymphoma Study Group performed a phase II study using R-ICE to treat 28 pediatric patients with relapsed/refractory B-cell NHL.[47]
The investigators observed a complete and partial response rate of 70%.
A retrospective review of patients with relapsed disease treated in the LMB-89, LMB-96, and LMB-2001 trials were analyzed. Group A and group B patients received the CYVE regimen as initial salvage therapy, and group C patients received ICE with or without rituximab.[38]
Sources: 38
A retrospective review of patients with relapsed disease treated in the LMB-89, LMB-96, and LMB-2001 trials were analyzed. Group A and group B patients received the CYVE regimen as initial salvage therapy, and group C patients received ICE with or without rituximab.[38]
The complete and partial remission rate was 64%; 2 of 3 group A patients responded, 19 of 29 group B patients responded, and 3 of 5 group C patients responded.
A retrospective review of patients with relapsed Burkitt lymphoma treated initially with BFM therapy noted that patients who were treated before the year 2000 had significantly inferior outcomes compared with those who were treated after 2000. The 5-year overall survival (OS) rates were 11% for those treated before the year 2000, compared with 27% for those treated after 2000. The 75 patients treated after 2000 were analyzed further, with the following results:[37][Level of evidence C1]
Sources: 37 · Level of evidence C1
A retrospective review of patients with relapsed Burkitt lymphoma treated initially with BFM therapy noted that patients who were treated before the year 2000 had significantly inferior outcomes compared with those who were treated after 2000. The 5-year overall survival (OS) rates were 11% for those treated before the year 2000, compared with 27% for those treated after 2000. The 75 patients treated after 2000 were analyzed further, with the following results:[37][Level of evidence C1]
Of the 75 patients, 29 (41%) had leukemic involvement.
Median time to relapse was 0.4 years after diagnosis. More than one-third of patients relapsed during initial treatment.
Reinduction therapy was variable; 65% of patients proceeded to either autologous or allogeneic HSCT.
Reinduction with intensive continuous chemotherapy with R-VICI therapy before HSCT improved survival (4-year OS rate, 67%).
Initial disease risk category was prognostic: Low-risk patients (R1/R2) had improved survival (4-year OS rate, 50%), compared with high-risk patients (R3/R4; 4-year OS rate, 21%).
First-line therapy was also prognostic: 25 of 28 patients with progression during first-line therapy died, and 9 of 10 patients who were treated with front-line rituximab died.
Complete remission before HSCT was prognostic (4-year OS rate, 63%).
There are limited data for CAR T-cell therapy in pediatric patients with Burkitt lymphoma and diffuse large B-cell lymphoma. A single-center experience included 23 children with relapsed or refractory Burkitt lymphoma who were treated sequentially with three CAR T cells (CD19, CD22, and CD20). Patients were followed every 2 weeks, and they received subsequent CAR T cells if CAR T cells were not detectable in the blood or there was evidence of disease progression.[45]
Sources: 45
There are limited data for CAR T-cell therapy in pediatric patients with Burkitt lymphoma and diffuse large B-cell lymphoma. A single-center experience included 23 children with relapsed or refractory Burkitt lymphoma who were treated sequentially with three CAR T cells (CD19, CD22, and CD20). Patients were followed every 2 weeks, and they received subsequent CAR T cells if CAR T cells were not detectable in the blood or there was evidence of disease progression.[45]
The 18-month complete response and PFS rates were 78%.
These results may be due to short (1 week) CAR T-cell manufacture time and/or sequential antigen targeting.
The sustained complete response rates were 39% (9 of 23) for CD19 CAR T cells, 38% (5 of 13) for CD22 CAR T cells, and 50% (3 of 6) for CD20 CAR T cells.
The median follow-up was only 17 months.
If remission can be achieved, high-dose therapy plus HSCT remains the best option for survival. Patients not in remission at the time of transplant fare significantly worse.[38,41,46,48-50] The very poor outcome of patients whose disease is refractory to salvage chemotherapy suggests that a nonexperimental transplant option should not be pursued in these patients.[41,49,50] If a complete remission was reported, survival ranges between 30% to 75%, albeit all series have a small number of patients (i.e., fewer than 40).[41,46,47,49,51] The benefit of autologous versus allogeneic HSCT remains unclear.[36,41,51,52]; [48][Level of evidence B4]; [53][Level of evidence C2]
Sources: 38 · 41 · 46 · 48 · 50 · 41 · 49 · 50 · 41 · 46 · 47 · 49 · 51 · 36 · 41 · 51 · 52 · 48 · Level of evidence B4 · 53 · Level of evidence C2
For more information about transplant, see Pediatric Autologous Hematopoietic Stem Cell Transplant, Pediatric Allogeneic Hematopoietic Stem Cell Transplant, and Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer.
Sources: Pediatric Autologous Hematopoietic Stem Cell Transplant · Pediatric Allogeneic Hematopoietic Stem Cell Transplant · Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer
Evidence (HSCT therapy):
An analysis of data from the Center for International Blood and Marrow Transplant Research demonstrated the following:[41]
Sources: 41
An analysis of data from the Center for International Blood and Marrow Transplant Research demonstrated the following:[41]
No difference in outcome using either autologous or allogeneic donor stem cell sources.
The 2-year EFS rates were 50% for patients with diffuse large B-cell lymphoma and 30% for patients with Burkitt lymphoma who survived to undergo a transplant.
Some graft-versus-lymphoma effect has been implied by the lower relapse rate in the allogeneic HSCT patients. However, that effect was balanced by the higher treatment-related mortality.
A small, single-center, prospective study used autologous transplant followed by reduced-intensity allogeneic HSCT to treat patients with relapsed NHL.[42]
Sources: 42
A small, single-center, prospective study used autologous transplant followed by reduced-intensity allogeneic HSCT to treat patients with relapsed NHL.[42]
The study reported an EFS rate of 60%.
Treatment options under clinical evaluation for Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Treatment options for diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
As with Burkitt lymphoma, current treatment strategies are based on risk stratification, as described in Table 5. The treatment of diffuse large B-cell lymphoma is the same as the treatment of Burkitt lymphoma. For information about the treatment of diffuse large B-cell lymphoma, see the Standard treatment options for Burkitt lymphoma section.
Sources: Table 5 · Standard treatment options for Burkitt lymphoma
Radiation therapy can be considered for patients who are unresponsive to salvage therapies or as a consolidation therapy for select patients.[73]
Sources: 73
Treatment options for recurrent or refractory diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The treatment of recurrent diffuse large B-cell lymphoma is the same as the treatment of recurrent Burkitt lymphoma. For more information, see the Treatment options for recurrent or refractory Burkitt lymphoma section.
Sources: Treatment options for recurrent or refractory Burkitt lymphoma
Treatment options under clinical evaluation for diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Treatment options for primary mediastinal B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for primary mediastinal B-cell lymphoma include the following:
Chemotherapy and rituximab.
Sources: Chemotherapy and rituximab
Chemotherapy and rituximab.
DA-EPOCH-R.
Lymphome Malin de Burkitt (LMB)–based chemotherapy plus rituximab.
Radiation therapy.
Sources: Radiation therapy
Chemotherapy and rituximab
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Pediatric and adolescent patients with stage III primary mediastinal large B-cell lymphoma fared significantly worse on the FAB/LMB-96 (NCT00002757) study, with a 5-year EFS rate of 66%, compared with 85% for adolescents with nonmediastinal diffuse large B-cell lymphoma.[92][Level of evidence B4] Similarly, in the NHL-BFM-95 trial, patients with primary mediastinal B-cell lymphoma had an EFS rate of 50% at 3 years.[21] However, a study of young adults treated with DA-EPOCH-R showed excellent disease-free survival rates.[93]
Sources: FAB/LMB-96 (NCT00002757) · 92 · Level of evidence B4 · 21 · 93
Evidence (DA-EPOCH-R):
A single-arm study in young adults used the DA-EPOCH-R regimen (usually six cycles) with filgrastim and no radiation therapy.[93][Level of evidence B4]
Sources: 93 · Level of evidence B4
A single-arm study in young adults used the DA-EPOCH-R regimen (usually six cycles) with filgrastim and no radiation therapy.[93][Level of evidence B4]
The 5-year EFS rate was 93%, and the OS rate was 97%.
At short-term follow-up, there was no evidence of cardiac toxicity, despite a high cumulative dose of doxorubicin for those who received most of the anthracycline-dose escalations.
An important finding in this study was the prognostic value of end-of-therapy imaging. Nine of 12 patients who had residual mediastinal masses at the end of therapy had positive positron emission tomography scans. Seven of these nine patients had the masses resected, but no viable tumor was found.
A concern for using this regimen is the significantly higher cumulative doses of alkylating agents and anthracyclines administered than those used in previous regimens.
A multicenter retrospective study of 38 pediatric patients (aged <21 years) and 118 adult patients treated with DA-EPOCH-R observed the following:[94]
Sources: 94
A multicenter retrospective study of 38 pediatric patients (aged <21 years) and 118 adult patients treated with DA-EPOCH-R observed the following:[94]
Pediatric patients had a 3-year EFS rate of 81% and a 3-year OS rate of 91%. These results were not significantly different from the results observed in adults.
A prospective international study included 46 patients (aged <18 years) who were treated with DA-EPOCH-R. The study demonstrated the following results:[95]
Sources: 95
A prospective international study included 46 patients (aged <18 years) who were treated with DA-EPOCH-R. The study demonstrated the following results:[95]
The 4-year EFS rate was 70%, and the 3-year OS rate was 85%.
These outcomes were lower than those in other studies that treated patients with DA-EPOCH-R and were not statistically different from the results of the FAB/LMB-96 (NCT00002757) trial, when a Burkitt lymphoma therapy was used.
Sources: FAB/LMB-96 (NCT00002757)
The ability to dose escalate and the adverse events were similar to what has been reported in adult patients.
Evidence (LMB-based chemotherapy plus rituximab):
The French prospective LMB2001 study reported the outcomes of patients with primary mediastinal B-cell lymphoma who were treated with LMB-based chemotherapy without radiation therapy. There were 773 patients with B-cell NHL, including 42 patients with primary mediastinal B-cell lymphoma, treated between 2001 and 2012. In 2008, the investigators recommended treating all patients with primary mediastinal B-cell lymphoma with rituximab on day 1 of each course. Additionally, patients with bulky mediastinal adenopathy (>10 cm) and/or high LDH serum level (>2N on the Institution upper limit value), and/or lomboaortic nodes were assigned to Group C1 therapy. After 2010, patients with primary mediastinal B-cell lymphoma were treated with a hybrid Group B/C therapy. In total, 21 of 42 patients received rituximab. Nineteen patients were treated with Group B therapy, 18 with Group C therapy, and 5 with Group B/C therapy. The median follow-up was 7.1 years for the entire cohort, 10.6 years for patients who did not receive rituximab, and 6.4 years for patients treated with rituximab.[96]
Sources: 96
The French prospective LMB2001 study reported the outcomes of patients with primary mediastinal B-cell lymphoma who were treated with LMB-based chemotherapy without radiation therapy. There were 773 patients with B-cell NHL, including 42 patients with primary mediastinal B-cell lymphoma, treated between 2001 and 2012. In 2008, the investigators recommended treating all patients with primary mediastinal B-cell lymphoma with rituximab on day 1 of each course. Additionally, patients with bulky mediastinal adenopathy (>10 cm) and/or high LDH serum level (>2N on the Institution upper limit value), and/or lomboaortic nodes were assigned to Group C1 therapy. After 2010, patients with primary mediastinal B-cell lymphoma were treated with a hybrid Group B/C therapy. In total, 21 of 42 patients received rituximab. Nineteen patients were treated with Group B therapy, 18 with Group C therapy, and 5 with Group B/C therapy. The median follow-up was 7.1 years for the entire cohort, 10.6 years for patients who did not receive rituximab, and 6.4 years for patients treated with rituximab.[96]
The 5-year EFS rate was 88.1% (95% CI, 75%–94.8%) for the whole cohort.
The French prospective LMB2001 study reported the outcomes of patients with primary mediastinal B-cell lymphoma who were treated with LMB-based chemotherapy without radiation therapy. There were 773 patients with B-cell NHL, including 42 patients with primary mediastinal B-cell lymphoma, treated between 2001 and 2012. In 2008, the investigators recommended treating all patients with primary mediastinal B-cell lymphoma with rituximab on day 1 of each course. Additionally, patients with bulky mediastinal adenopathy (>10 cm) and/or high LDH serum level (>2N on the Institution upper limit value), and/or lomboaortic nodes were assigned to Group C1 therapy. After 2010, patients with primary mediastinal B-cell lymphoma were treated with a hybrid Group B/C therapy. In total, 21 of 42 patients received rituximab. Nineteen patients were treated with Group B therapy, 18 with Group C therapy, and 5 with Group B/C therapy. The median follow-up was 7.1 years for the entire cohort, 10.6 years for patients who did not receive rituximab, and 6.4 years for patients treated with rituximab.[96] › The 5-year EFS rate was 88.1% (95% CI, 75%–94.8%) for the whole cohort.
The 5-year EFS rate was 81% (95% CI, 60%–92.3%) for patients who did not receive rituximab.
The 5-year EFS rate was 95.2% (95% CI, 77.3%–99.2%) for patients who received rituximab.
The French prospective LMB2001 study reported the outcomes of patients with primary mediastinal B-cell lymphoma who were treated with LMB-based chemotherapy without radiation therapy. There were 773 patients with B-cell NHL, including 42 patients with primary mediastinal B-cell lymphoma, treated between 2001 and 2012. In 2008, the investigators recommended treating all patients with primary mediastinal B-cell lymphoma with rituximab on day 1 of each course. Additionally, patients with bulky mediastinal adenopathy (>10 cm) and/or high LDH serum level (>2N on the Institution upper limit value), and/or lomboaortic nodes were assigned to Group C1 therapy. After 2010, patients with primary mediastinal B-cell lymphoma were treated with a hybrid Group B/C therapy. In total, 21 of 42 patients received rituximab. Nineteen patients were treated with Group B therapy, 18 with Group C therapy, and 5 with Group B/C therapy. The median follow-up was 7.1 years for the entire cohort, 10.6 years for patients who did not receive rituximab, and 6.4 years for patients treated with rituximab.[96]
The 5-year OS rate was 95.2% for the whole cohort.
The French prospective LMB2001 study reported the outcomes of patients with primary mediastinal B-cell lymphoma who were treated with LMB-based chemotherapy without radiation therapy. There were 773 patients with B-cell NHL, including 42 patients with primary mediastinal B-cell lymphoma, treated between 2001 and 2012. In 2008, the investigators recommended treating all patients with primary mediastinal B-cell lymphoma with rituximab on day 1 of each course. Additionally, patients with bulky mediastinal adenopathy (>10 cm) and/or high LDH serum level (>2N on the Institution upper limit value), and/or lomboaortic nodes were assigned to Group C1 therapy. After 2010, patients with primary mediastinal B-cell lymphoma were treated with a hybrid Group B/C therapy. In total, 21 of 42 patients received rituximab. Nineteen patients were treated with Group B therapy, 18 with Group C therapy, and 5 with Group B/C therapy. The median follow-up was 7.1 years for the entire cohort, 10.6 years for patients who did not receive rituximab, and 6.4 years for patients treated with rituximab.[96] › The 5-year OS rate was 95.2% for the whole cohort.
The 5-year OS rate was 90.5% for patients who did not receive rituximab.
The 5-year OS rate was 100% for patients who received rituximab.
Radiation therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Primary mediastinal B-cell lymphoma in adults is currently and primarily treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy, adult patients receive radiation therapy if they have a residual abnormality that is concerning for active tumor. Although most patients with primary mediastinal B-cell lymphoma demonstrate residual tissue abnormalities at the end of chemoimmunotherapy, this does not definitively indicate active tumor. Positron emission tomography–computed tomography (PET-CT) scans are useful to differentiate active tumor from fibrotic tissue in patients treated for mediastinal lymphoma.
Although lymphoma is responsive to radiation therapy, the role of radiation therapy has not been clearly determined in the up-front setting of primary mediastinal B-cell lymphoma. The results from a prospective randomized trial in adults with primary mediastinal B-cell lymphoma who were treated with R-CHOP with or without radiation therapy demonstrated that patients assigned to radiation therapy had a superior EFS, with no differences in PFS and OS.[97] The role of radiation therapy is less clear in the setting of more dose-intensive regimens that contain rituximab, such as DA-EPOCH-R.
Sources: 97
Pediatric data are limited on the use of radiation therapy in the initial management of primary mediastinal B-cell lymphoma. Prospective pediatric studies that did not include radiation therapy have been conducted. In a retrospective analysis on the use of DA-EPOCH-R, radiation therapy was only administered in a small subset of pediatric patients (4 of 36 patients), highlighting the limited use of radiation therapy among pediatric patients treated outside of clinical trials.[94] The management of primary mediastinal B-cell lymphoma in pediatric patients, as with other childhood cancers, requires considering the efficacy and the long-term toxicity of the treatment. In particular, the potential for cardiac and pulmonary toxicities and secondary malignancies must be considered. More intensive chemotherapy regimens may allow for omitting radiation therapy but may also increase cardiac toxicity.
Sources: 94
Treatment options for recurrent or refractory primary mediastinal B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The U.S. Food and Drug Administration granted accelerated approval of pembrolizumab for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or who have relapsed after two or more previous lines of therapy. The approval was based on data from 53 patients (median age, 33 years; range, 20–61 years). The overall response rate was 41%, which included 12% complete responses and 29% partial responses.[98]
Sources: 98
Treatment options under clinical evaluation for primary mediastinal B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ANHL1931 (NCT04759586) (Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma): This phase III trial compares the effects of nivolumab combined with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma. Patients treated with R-CHOP or who have biopsy-proven, end-of-therapy disease are permitted to undergo consolidative radiation therapy.
Sources: ANHL1931 (NCT04759586)
Standard Treatment Options for Lymphoblastic Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Low-stage (stage I or stage II) lymphoblastic lymphoma is primarily a B-cell disease. Treatment with short, pulsed chemotherapy (i.e., doxorubicin, cyclophosphamide, vincristine, and prednisone [CHOP]), followed by 6 months of maintenance therapy, produces a disease-free survival (DFS) rate of about 60% and an overall survival (OS) rate exceeding 90%.[16,17] However, the use of an ALL treatment approach, consisting of induction, consolidation, and maintenance therapy for a total of 24 months, has produced DFS rates higher than 90% in children with low-stage lymphoblastic lymphoma.[6,18,19]
Patients with high-stage (stage III or stage IV) lymphoblastic lymphoma, most often T-cell disease, have DFS rates higher than 80%.[18-20] Mediastinal involvement is common, but radiation therapy is not necessary for patients with mediastinal masses, except in the emergency treatment of symptomatic superior vena cava obstruction or airway obstruction. In these cases, either corticosteroid therapy or low-dose radiation therapy is usually given. For more information, see the Mediastinal masses section.
Sources: 18 · 20 · Mediastinal masses
The following studies have contributed to the development of current treatment regimens for pediatric patients with lymphoblastic lymphoma.
The Pediatric Oncology Group conducted a trial to test the effectiveness of high-dose methotrexate in the treatment of patients with T-ALL and T-cell lymphoblastic lymphoma. In the lymphoma patients (n = 66), high-dose methotrexate did not demonstrate a benefit, with a 5-year event-free survival (EFS) rate of 88%.[21][Level of evidence A1] Of note, all of these patients received prophylactic cranial radiation therapy, even though other studies have shown that it is not required for patients with T-cell lymphoblastic lymphoma.[19,20] In this study, the benefit of adding the cardioprotectant dexrazoxane was tested in a randomized fashion. The addition of dexrazoxane did not affect patient outcomes, and it provided cardioprotective benefits, as demonstrated by echocardiographic and laboratory assessments.[22][Level of evidence B4]
Sources: 21 · Level of evidence A1 · 19 · 20 · 22 · Level of evidence B4
In the NHL-BFM-90 study, the 5-year DFS rate was 90%, and there was no difference in outcome between patients with stage III and stage IV disease.[18] Patients with precursor B-cell lymphoblastic lymphoma appeared to have similar results using the same therapy.[2] All patients received prophylactic cranial radiation therapy. In the NHL-BFM-95 study, the amount of daunorubicin and asparaginase in induction was reduced and patients did not receive prophylactic cranial radiation therapy.[19] The DFS rate in this study was similar to the rate in the NHL-BFM-90 study. However, the EFS rate was lower, at 82%, because of a higher incidence of subsequent neoplasms.[19] A single-center study reported that patients treated for lymphoblastic lymphoma had a higher incidence of subsequent neoplasms than did patients treated for other pediatric NHL.[23] However, studies from the Children's Oncology Group (COG) and the Childhood Cancer Survivor Study Group did not support this finding.[20,24-26]
Evidence for chemotherapy (low-stage treatment regimens for lymphoblastic lymphoma):
COG-A5971 (NCT00004228): Stage I or stage II patients (arm A0; localized disease) received a modified Children's Cancer Group (CCG) BFM regimen and a reduced number of intrathecal treatments during the maintenance phase.[6]
Sources: COG-A5971 (NCT00004228) · 6
COG-A5971 (NCT00004228): Stage I or stage II patients (arm A0; localized disease) received a modified Children's Cancer Group (CCG) BFM regimen and a reduced number of intrathecal treatments during the maintenance phase.[6]
In 56 patients, the 5-year EFS rate was 90%, and the OS rate was 96%.
Evidence for chemotherapy (high-stage treatment regimens for lymphoblastic lymphoma):
GER-GPOH-NHL-BFM-95: Only CNS-positive patients received CNS radiation therapy. The treatment duration for patients with T-cell and B-cell precursor lymphoblastic lymphoma was 24 months.[18,19]
GER-GPOH-NHL-BFM-95: Only CNS-positive patients received CNS radiation therapy. The treatment duration for patients with T-cell and B-cell precursor lymphoblastic lymphoma was 24 months.[18,19]
The 5-year DFS rate was 88%, and the OS rate was 85%.
COG-A5971 (NCT00004228): This trial evaluated two strategies for CNS prophylaxis, without the use of CNS irradiation, for patients with stage III and stage IV lymphoblastic lymphoma. Patients were randomly assigned to receive either high-dose methotrexate during the interim maintenance phase (BFM-95) or intrathecal chemotherapy throughout the maintenance phase (CCG-BFM).[20][Level of evidence A1]Equivalent outcomes were observed for patients treated on arms A1, B1, A2, and B2. The 5-year EFS rates were 81%, 80%, 84%, and 80%, respectively. The OS rates were 84%, 88%, 85%, and 85%, respectively. Patients with CNS disease at diagnosis had a 5-year EFS rate of 63% and an OS rate of 81%.
Sources: COG-A5971 (NCT00004228) · 20 · Level of evidence A1
COG-A5971 (NCT00004228): This trial evaluated two strategies for CNS prophylaxis, without the use of CNS irradiation, for patients with stage III and stage IV lymphoblastic lymphoma. Patients were randomly assigned to receive either high-dose methotrexate during the interim maintenance phase (BFM-95) or intrathecal chemotherapy throughout the maintenance phase (CCG-BFM).[20][Level of evidence A1]Equivalent outcomes were observed for patients treated on arms A1, B1, A2, and B2. The 5-year EFS rates were 81%, 80%, 84%, and 80%, respectively. The OS rates were 84%, 88%, 85%, and 85%, respectively. Patients with CNS disease at diagnosis had a 5-year EFS rate of 63% and an OS rate of 81%.
First randomization:
COG-A5971 (NCT00004228): This trial evaluated two strategies for CNS prophylaxis, without the use of CNS irradiation, for patients with stage III and stage IV lymphoblastic lymphoma. Patients were randomly assigned to receive either high-dose methotrexate during the interim maintenance phase (BFM-95) or intrathecal chemotherapy throughout the maintenance phase (CCG-BFM).[20][Level of evidence A1]Equivalent outcomes were observed for patients treated on arms A1, B1, A2, and B2. The 5-year EFS rates were 81%, 80%, 84%, and 80%, respectively. The OS rates were 84%, 88%, 85%, and 85%, respectively. Patients with CNS disease at diagnosis had a 5-year EFS rate of 63% and an OS rate of 81%. › First randomization:
Arm A1 (disseminated disease, no CNS disease): Modified CCG-BFM regimen without intensification. No high-dose methotrexate was administered during the interim maintenance phase, but intrathecal therapy was administered throughout the maintenance phase.
Arm B1 (disseminated disease, no CNS disease): GER-GPOH-NHL-BFM-95 regimen without intensification and without intrathecal therapy during the maintenance phase.
COG-A5971 (NCT00004228): This trial evaluated two strategies for CNS prophylaxis, without the use of CNS irradiation, for patients with stage III and stage IV lymphoblastic lymphoma. Patients were randomly assigned to receive either high-dose methotrexate during the interim maintenance phase (BFM-95) or intrathecal chemotherapy throughout the maintenance phase (CCG-BFM).[20][Level of evidence A1]Equivalent outcomes were observed for patients treated on arms A1, B1, A2, and B2. The 5-year EFS rates were 81%, 80%, 84%, and 80%, respectively. The OS rates were 84%, 88%, 85%, and 85%, respectively. Patients with CNS disease at diagnosis had a 5-year EFS rate of 63% and an OS rate of 81%.
Second randomization:
COG-A5971 (NCT00004228): This trial evaluated two strategies for CNS prophylaxis, without the use of CNS irradiation, for patients with stage III and stage IV lymphoblastic lymphoma. Patients were randomly assigned to receive either high-dose methotrexate during the interim maintenance phase (BFM-95) or intrathecal chemotherapy throughout the maintenance phase (CCG-BFM).[20][Level of evidence A1]Equivalent outcomes were observed for patients treated on arms A1, B1, A2, and B2. The 5-year EFS rates were 81%, 80%, 84%, and 80%, respectively. The OS rates were 84%, 88%, 85%, and 85%, respectively. Patients with CNS disease at diagnosis had a 5-year EFS rate of 63% and an OS rate of 81%. › Second randomization:
Arm A2 (disseminated disease, no CNS disease): Modified CCG-BFM regimen (arm A1) with intensified induction and delayed intensification.
Arm B2 (disseminated disease, no CNS disease): GER-GPOH-NHL-BFM-95 regimen (arm B1) with intensified induction and delayed intensification. Patients with CNS disease were nonrandomly treated on arm B2 with the addition of radiation therapy.
COG AALL0434 (NCT00408005): In this trial, patients with stages II to IV T-cell lymphoblastic lymphoma received COG-augmented, BFM-backbone therapy with Capizzi methotrexate and intrathecal chemotherapy through the maintenance phase. No patients with CNS disease received cranial radiation therapy because patients with CNS3 disease were not eligible. Patients with less than 1% minimal disseminated disease (MDD) in their bone marrow at diagnosis, assessed by flow cytometry, were nonrandomly assigned to treatment without nelarabine. Patients with greater than 1% MDD were randomly assigned to receive treatment with or without nelarabine.[26]
Sources: AALL0434 (NCT00408005) · 26
COG AALL0434 (NCT00408005): In this trial, patients with stages II to IV T-cell lymphoblastic lymphoma received COG-augmented, BFM-backbone therapy with Capizzi methotrexate and intrathecal chemotherapy through the maintenance phase. No patients with CNS disease received cranial radiation therapy because patients with CNS3 disease were not eligible. Patients with less than 1% minimal disseminated disease (MDD) in their bone marrow at diagnosis, assessed by flow cytometry, were nonrandomly assigned to treatment without nelarabine. Patients with greater than 1% MDD were randomly assigned to receive treatment with or without nelarabine.[26]
The overall 4-year DFS rate was 85%, and the OS rate was 89%.
There was no difference in DFS observed between standard-risk and high-risk patients. Disease stage and MDD status at diagnosis also did not demonstrate differences in EFS.
Although nelarabine was beneficial in patients with T-ALL, there was no statistical difference in outcome for patients with NHL who did or did not receive nelarabine. This result may be explained by small numbers of randomized NHL patients or lower CNS relapse rates in NHL patients (i.e., 1.4%).
COG AALL1231 (NCT02112916): Patients who were newly diagnosed with T-cell lymphoblastic lymphoma were treated with the AALL0434 backbone, with some treatment modifications. Dexamethasone was given instead of prednisone in the induction and maintenance phases, and two additional pegaspargase doses were given during the induction and delayed intensification phases. Patients were randomly assigned to receive treatment with or without bortezomib (four doses in induction and four doses in delayed intensification).[27]
Sources: AALL1231 (NCT02112916) · 27
COG AALL1231 (NCT02112916): Patients who were newly diagnosed with T-cell lymphoblastic lymphoma were treated with the AALL0434 backbone, with some treatment modifications. Dexamethasone was given instead of prednisone in the induction and maintenance phases, and two additional pegaspargase doses were given during the induction and delayed intensification phases. Patients were randomly assigned to receive treatment with or without bortezomib (four doses in induction and four doses in delayed intensification).[27]
There was an increased rate of toxic deaths in the AALL1231 trial (4%), compared with the AALL0434 trial (2%).
Patients who received bortezomib had statistically significantly better 4-year EFS rates than those who did not receive bortezomib (EFS rates, 86% vs. 76%; P = .04). However, patients in the bortezomib arm had EFS and OS rates similar to patients in both arms of the AALL0434 trial, who were treated with and without nelarabine.
The poorer-than-expected outcome for patients treated without bortezomib cannot be explained solely by an increased toxic death rate. Despite more intensive therapy in the AALL1231 trial than in the AALL0434 trial, more relapses were observed in AALL1231.
Treatment Options for Recurrent or Refractory Lymphoblastic Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
For patients with recurrent or refractory lymphoblastic lymphoma, survival rates range from 10% to 40%.[24,28]; [29][Level of evidence B4]; [30,31][Level of evidence C1] As in patients with Burkitt lymphoma, chemoresistant disease is common.
Sources: 24 · 28 · 29 · Level of evidence B4 · 30 · 31 · Level of evidence C1
There are no standard treatment options for patients with recurrent or refractory disease.
Treatment options for recurrent or refractory lymphoblastic lymphoma include the following:
Nelarabine or nelarabine-containing chemotherapy regimens (nelarabine, cyclophosphamide, and etoposide).[32-35]
ICE regimen (ifosfamide, carboplatin, and etoposide).[36]
Sources: 36
Bortezomib with block 1 (four-drug induction), block 2 (cyclophosphamide, etoposide, and high-dose methotrexate), and block 3 (high-dose cytarabine and PEG-asparaginase).[37]
Sources: 37
Daratumumab with chemotherapy.[38]
Sources: 38
Evidence (treatment of recurrent or refractory lymphoblastic lymphoma):
A COG phase II study of nelarabine (compound 506U78) as a single agent demonstrated a response rate of 40%.[32]
Sources: 32
A phase IV multicenter study of patients with recurrent or refractory T-cell leukemia/lymphoma (n = 28, 11 lymphoma) were treated with single-agent nelarabine.[33]
Sources: 33
A phase IV multicenter study of patients with recurrent or refractory T-cell leukemia/lymphoma (n = 28, 11 lymphoma) were treated with single-agent nelarabine.[33]
A complete response rate of 36% was observed.
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42]
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42]
One study treated 27 patients.[34]
Sources: 34
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42] › One study treated 27 patients.[34]
A partial/complete response rate of 85% was observed.
However, 13% of patients developed greater than grade 3 neurotoxicity, and three patients died of neurotoxicity.
Of the four lymphoma patients, one patient achieved a partial remission, but all patients eventually had disease progression.
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42]
The second study treated seven patients.[41]
Sources: 41
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42] › The second study treated seven patients.[41]
The partial/complete response rate was 100%.
Of the two lymphoma patients, both achieved partial responses but later progressed.
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42]
The third study treated ten patients.[42]
Sources: 42
Three small series have treated patients with recurrent or refractory T-cell leukemia/lymphoma using nelarabine, cyclophosphamide, and etoposide.[34,41,42] › The third study treated ten patients.[42]
Forty-four percent of the patients had any response (complete response, complete response with incomplete platelet recovery, or partial response), and the complete response rate was 33%.
Two of ten patients had severe peripheral neuropathy.
On the AALL07P1 (NCT00873093) trial, ten patients with T-cell lymphoblastic lymphoma in first relapse were treated with bortezomib added to a four-drug induction regimen.[37]
Sources: AALL07P1 (NCT00873093) · 37
On the AALL07P1 (NCT00873093) trial, ten patients with T-cell lymphoblastic lymphoma in first relapse were treated with bortezomib added to a four-drug induction regimen.[37]
Seven patients had a response; one patient had a complete response, two patients had unconfirmed complete responses, and four patients had partial responses.
An international collaboration studied the use of daratumumab plus two cycles of chemotherapy in ten patients with relapsed or refractory T-cell lymphoblastic lymphoma.[38]
Sources: 38
An international collaboration studied the use of daratumumab plus two cycles of chemotherapy in ten patients with relapsed or refractory T-cell lymphoblastic lymphoma.[38]
The overall response rate was 50%, with a 40% complete response rate.
The addition of daratumumab did not significantly increase the toxicity of the chemotherapy, but most patients experienced infusion-related toxicity (70%; grades 1 and 2).
A BFM study showed an OS rate of 14% for patients relapsing after BFM front-line therapy. All patients who survived had undergone an allogeneic HSCT.[31]
Sources: 31
A Center for International Blood and Marrow Transplant Research analysis demonstrated that the EFS rate was significantly worse when an autologous (4%) versus allogeneic (40%) donor stem cell source was used. All treatment failures resulted from progressive disease.[39]
Sources: 39
Treatment Options Under Clinical Evaluation for Lymphoblastic Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Standard Treatment Options for Anaplastic Large Cell Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Children and adolescents with high-stage (stage III or IV) anaplastic large cell lymphoma have a disease-free survival rate of approximately 60% to 75%.[14-19]
It is unclear which treatment strategy is best for patients with anaplastic large cell lymphoma. Current data do not suggest superiority of one treatment regimen over another for these standard treatment options.
Commonly used treatment regimens include the following:
POG-8314/POG-8719/POG 9219: Three cycles of chemotherapy (no radiation or maintenance therapy) for stage I and stage II disease.[20]
Sources: 20
GER-GPOH-NHL-BFM-90: Prephase plus three cycles of chemotherapy (only for completely resected disease).[15]
Sources: 15
APO regimen: Doxorubicin, prednisone, and vincristine.[16] This regimen can be administered in the outpatient setting. The duration of therapy is 52 weeks, and the cumulative dose of doxorubicin is 300 mg/m2. No alkylator therapy is given.
Sources: 16
FRE-IGR-ALCL99: Dexamethasone, cyclophosphamide, ifosfamide, etoposide, doxorubicin, intravenous (IV) methotrexate (3 g/m2 in one study arm), cytarabine, prednisolone, and vinblastine.[21] This regimen usually requires hospitalization for administration. The total duration of therapy is 5 months, and the cumulative dose of doxorubicin is 150 mg/m2.
Sources: FRE-IGR-ALCL99 · 21
Evidence (treatment of anaplastic large cell lymphoma):
The POG-9219 study for patients with low-stage lymphoma used three cycles of doxorubicin, cyclophosphamide, vincristine, and prednisone (CHOP).[20]
Sources: 20
The POG-9219 study for patients with low-stage lymphoma used three cycles of doxorubicin, cyclophosphamide, vincristine, and prednisone (CHOP).[20]
The 5-year event-free survival (EFS) rate was 88% for patients with large cell lymphoma (anaplastic large cell lymphoma and diffuse large B-cell lymphoma).
The FRE-IGR-ALCL99 trial used three cycles of chemotherapy after cytoreductive prophase for patients with stage I, completely resected disease. The therapy for patients without complete resection was the same as the therapy for patients with disseminated disease.[22][Level of evidence B4]
Sources: FRE-IGR-ALCL99 · 22 · Level of evidence B4
The FRE-IGR-ALCL99 trial used three cycles of chemotherapy after cytoreductive prophase for patients with stage I, completely resected disease. The therapy for patients without complete resection was the same as the therapy for patients with disseminated disease.[22][Level of evidence B4]
Only 6 of 36 patients with stage I disease had complete resections. No treatment failures were reported for these 6 patients.
The 3-year EFS (77%) and overall survival (OS) (97%) rates for patients without complete resections were not statistically different from the outcomes for patients with higher-stage disease.
The German Berlin-Frankfurt-Münster (BFM) group used six cycles of intensive pulsed therapy, similar to their B-cell NHL therapy (GER-GPOH-NHL-BFM-90 [NHL-BFM-90]).[15,23,24]; [21][Level of evidence A1] Building on these results, the European Intergroup for Childhood NHL group conducted the FRE-IGR-ALCL99 study (based on the GER-GPOH-NHL-BFM-90 regimen).
Sources: 15 · 23 · 24 · 21 · Level of evidence A1 · FRE-IGR-ALCL99
The German Berlin-Frankfurt-Münster (BFM) group used six cycles of intensive pulsed therapy, similar to their B-cell NHL therapy (GER-GPOH-NHL-BFM-90 [NHL-BFM-90]).[15,23,24]; [21][Level of evidence A1] Building on these results, the European Intergroup for Childhood NHL group conducted the FRE-IGR-ALCL99 study (based on the GER-GPOH-NHL-BFM-90 regimen).
First, this randomized study demonstrated that methotrexate 1 g/m2 infused over 24 hours plus intrathecal methotrexate and methotrexate 3 g/m2 infused over 3 hours without intrathecal methotrexate yielded similar outcomes.[23][Level of evidence A3] However, methotrexate 3 g/m2 over 3 hours had less toxicity than methotrexate 1 g/m2 over 24 hours.[23]; [21][Level of evidence B1]
Sources: 23 · Level of evidence A3 · 23 · 21 · Level of evidence B1
Second, patients in the FRE-IGR-ALCL99 trial were randomly assigned to receive either limited vinblastine or prolonged (1 year) vinblastine exposure. Patients who received the vinblastine-plus-chemotherapy regimen had a better EFS rate in the first year after therapy (91%) than did those who did not receive vinblastine (74%). However, after 2 years of follow-up, the EFS rate was 73% for both groups.[24][Level of evidence B1] This suggests that the longer therapy in the vinblastine group delayed, but did not prevent, relapse.
Sources: 24 · Level of evidence B1
The COG-ANHL0131 (NCT00059839) trial showed that the addition of vinblastine to the doxorubicin, prednisone, and vincristine (APO) regimen increased toxicity, but did not improve the survival of patients with anaplastic large cell lymphoma.[13]
Sources: COG-ANHL0131 (NCT00059839) · 13
The earlier Pediatric Oncology Group (POG) trial (POG-9317) demonstrated no benefit of adding methotrexate and high-dose cytarabine to 52 weeks of the APO regimen.[16]
Sources: 16
The Italian Association of Pediatric Hematology/Oncology group used a leukemia-like regimen for 24 months in the LNH-92 trial. The results of this study were similar to those of studies that used other regimens, although the duration of first remission was prolonged by the longer therapy.[17]
Sources: 17
The CCG-5941 study tested an approach similar to that used in the LNH-92 trial, with more intensive induction and consolidation with maintenance for a total duration of therapy of 1 year. Similar outcomes and similar significant increase in hematologic toxicity were observed.[18][Level of evidence B4]
Sources: CCG-5941 · 18 · Level of evidence B4
One arm of the COG ANHL12P1 (NCT01979536) study added brentuximab vedotin to the ALCL99 trial chemotherapy backbone, and 68 patients were enrolled.[25]
Sources: ANHL12P1 (NCT01979536) · ALCL99 · 25
One arm of the COG ANHL12P1 (NCT01979536) study added brentuximab vedotin to the ALCL99 trial chemotherapy backbone, and 68 patients were enrolled.[25]
Patients who received the brentuximab vedotin–containing regimen had a 2-year EFS rate of 79% (95% confidence interval [CI], 67%–87%) and an OS rate of 97% (95% CI, 88%–99%). Patients who received the ALCL99 trial therapy without brentuximab vedotin had an estimated 5-year progression-free survival (PFS) rate of approximately 70%.
All events occurred after completion of therapy, with median time from diagnosis to relapse of 7.5 months (range, 5.5–22.0 months).
The addition of brentuximab vedotin to ALCL99 trial chemotherapy produced toxicity similar to what was observed in the ALCL99 trial.
This study confirmed the poor prognosis associated with minimal disseminated disease (MDD) in the peripheral blood at diagnosis. Patients with MDD (n = 22; 37%) had a 5-year EFS rate of 57.8%, compared with patients without MDD (n = 37; 63%) who had a 5-year EFS rate of 84.9%.
The second arm of the COG ANHL12P1 study added crizotinib to the ALCL99 trial chemotherapy backbone, and 66 patients were enrolled.[26]
The second arm of the COG ANHL12P1 study added crizotinib to the ALCL99 trial chemotherapy backbone, and 66 patients were enrolled.[26]
Patients who received the crizotinib-containing regimen had a 2-year EFS rate of 76.8% (95% CI, 68.5%–88.1%) and a 2-year OS rate of 95.2% (95% CI, 85.7%–98.4%). Patients who received ALCL99 trial therapy without crizotinib had an estimated 5-year PFS rate of approximately 70%.
All events occurred after completion of therapy, with median time from diagnosis to relapse of 7.4 months (range, 4.2–28.9 months).
The addition of crizotinib produced an unexpectedly high rate of thromboembolic events. Eleven of the first 41 patients (26.8%; 95% CI, 14.2%–42.9%) experienced grade 2 or higher thromboembolic adverse events. Among 25 patients enrolled after instituting mandatory prophylactic anticoagulation, 2 patients (8%) experienced grade 2 or higher thromboembolic events. Given the high rate of thromboembolic events, the authors recommend not using crizotinib with ALCL99 trial chemotherapy.
Patients with MDD in the peripheral blood at diagnosis (n = 20) had a 5-year EFS rate of 58.1%, while patients without MDD (n = 37) had a 5-year EFS rate of 85.6%.
CNS involvement in patients with anaplastic large cell lymphoma is rare at diagnosis. In an international study of systemic childhood anaplastic large cell lymphoma, 12 of 463 patients (2.6%) had CNS involvement, 3 of whom had isolated CNS disease (primary CNS lymphoma). For the CNS-positive group who received multiagent chemotherapy, including high-dose methotrexate, cytarabine, and intrathecal treatment, the EFS rate was 50% (95% CI, 25%–75%), and the OS rate was 74% (95% CI, 45%–91%) at a median follow-up of 4.1 years. The role of cranial radiation therapy has been difficult to assess.[27]
Sources: 27
Treatment Options for Recurrent or Refractory Anaplastic Large Cell Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Unlike mature B-cell or lymphoblastic lymphoma, the survival rates for patients with recurrent or refractory anaplastic large cell lymphoma are 40% to 80%.[28-32]
There is no standard approach for the treatment of recurrent or refractory anaplastic large cell lymphoma.
Treatment options for recurrent or refractory anaplastic large cell lymphoma include the following:
ICE regimen (ifosfamide, carboplatin, and etoposide).[33]
Sources: 33
Vinblastine.[34]
Sources: 34
Brentuximab vedotin.[35]; [36][Level of evidence B4]
Sources: 35 · 36 · Level of evidence B4
Crizotinib [37] and other ALK inhibitors (e.g., alectinib and ceritinib).[38,39]
Although remissions can be achieved with single-agent therapy (e.g., vinblastine, brentuximab vedotin, or crizotinib), CNS progressions after therapy have been observed in patients with recurrent anaplastic large cell lymphoma. A large retrospective review of a study database found that the incidence of CNS involvement at relapse is about 4%. The median time to relapse with CNS involvement was 8 months for 26 patients. The 3-year OS rate after relapse was about 50%.[43]
Sources: 43
Chemotherapy, followed by autologous or allogeneic HSCT, if remission can be achieved, has been used in this setting.[29,30,40,41,44]
Evidence (chemotherapy and targeted therapy):
Vinblastine is active as a single agent in patients with recurrent or refractory anaplastic large cell lymphoma.
Vinblastine is active as a single agent in patients with recurrent or refractory anaplastic large cell lymphoma.
In one study, patients with recurrent or refractory anaplastic large cell lymphoma were treated with vinblastine alone, and the following was observed:[34][Level of evidence C1]
Sources: 34 · Level of evidence C1
Vinblastine is active as a single agent in patients with recurrent or refractory anaplastic large cell lymphoma. › In one study, patients with recurrent or refractory anaplastic large cell lymphoma were treated with vinblastine alone, and the following was observed:[34][Level of evidence C1]
Vinblastine induced complete remission in 25 of 30 evaluable patients (83%).
Nine of these 25 patients remained in complete remission, with a median follow-up of 7 years from the end of treatment.
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein.
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein.
Crizotinib, a kinase inhibitor that blocks the activity of the NPM::ALK fusion protein, has been evaluated in children and adults with relapsed/refractory anaplastic large cell lymphoma.[45]
Sources: 45
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein. › Crizotinib, a kinase inhibitor that blocks the activity of the NPM::ALK fusion protein, has been evaluated in children and adults with relapsed/refractory anaplastic large cell lymphoma.[45]
Of 26 patients with anaplastic large cell lymphoma who were treated with crizotinib on a pediatric phase I study with a phase II extension, 21 patients achieved complete responses.[37,46][Level of evidence B4]
Sources: 37 · 46 · Level of evidence B4
Although complete responses are common, the duration of therapy remains unclear.[47][Level of evidence C2]
Sources: 47 · Level of evidence C2
The most common adverse event was neutropenia.[46]
Sources: 46
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein.
Alectinib is a second-generation ALK inhibitor that showed superiority over crizotinib in phase III studies for patients with ALK variants and non-small cell lung cancer.[48]
Sources: 48
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein. › Alectinib is a second-generation ALK inhibitor that showed superiority over crizotinib in phase III studies for patients with ALK variants and non-small cell lung cancer.[48]
In a study of ten patients with relapsed/refractory anaplastic large cell lymphoma, eight achieved objective responses, with six complete responses. Five patients achieved durable remissions (397–925 days at the time of the report) to alectinib as a single agent.[38]
Sources: 38
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein.
Ceritinib, an orally administered, second-generation ALK inhibitor, has been shown to be safe and effective in pediatric patients with ALK-positive tumors whose cancer relapsed. In a phase I dose-finding study, eight patients with anaplastic large cell lymphoma were evaluable for response.[39]
Sources: 39
ALK kinase inhibitors are highly active in patients with recurrent anaplastic large cell lymphoma that express the NPM::ALK fusion protein. › Ceritinib, an orally administered, second-generation ALK inhibitor, has been shown to be safe and effective in pediatric patients with ALK-positive tumors whose cancer relapsed. In a phase I dose-finding study, eight patients with anaplastic large cell lymphoma were evaluable for response.[39]
Twenty-five percent of the patients achieved a complete response, and 50% achieved a partial response.
Brentuximab vedotin has been evaluated in adults with anaplastic large cell lymphoma.
Brentuximab vedotin has been evaluated in adults with anaplastic large cell lymphoma.
In a phase II study of adults and adolescents with CD30-positive cancers, patients received a dose of 1.8 mg/kg of brentuximab vedotin every 3 weeks for approximately 1 year. The median age of patients was 52 years (range, 14–76 years). Sixteen of 58 patients (28%) had ALK-positive anaplastic large cell lymphoma, and 42 of 58 patients (72%) had ALK-negative anaplastic large cell lymphoma.[35]
Sources: 35
Brentuximab vedotin has been evaluated in adults with anaplastic large cell lymphoma. › In a phase II study of adults and adolescents with CD30-positive cancers, patients received a dose of 1.8 mg/kg of brentuximab vedotin every 3 weeks for approximately 1 year. The median age of patients was 52 years (range, 14–76 years). Sixteen of 58 patients (28%) had ALK-positive anaplastic large cell lymphoma, and 42 of 58 patients (72%) had ALK-negative anaplastic large cell lymphoma.[35]
Complete remission rates of approximately 55% to 60% and partial remission rates of 29% were observed.[35]
Sources: 35
For the 38 patients who achieved a complete remission (28 ALK-negative patients, 10 ALK-positive patients), the 5-year PFS rate was 79%, and the OS rate was 57%. PFS was similar for ALK-positive and ALK-negative patients.[49]
Sources: 49
Sixteen patients (11 ALK-negative patients, 5 ALK-positive patients) remained in remission without the start of new therapy other than consolidative HSCT at 5 or more years from the end of treatment with brentuximab vedotin. Of the five ALK-positive patients who remained in remission, four received an allogeneic HSCT, and one received no therapy other than brentuximab vedotin.[49]
Sources: 49
Brentuximab vedotin has been evaluated in children with recurrent or refractory anaplastic large cell lymphoma.
Brentuximab vedotin has been evaluated in children with recurrent or refractory anaplastic large cell lymphoma.
In a phase II study, 17 patients (median age, 11 years) were treated with brentuximab vedotin at a dose of 1.8 mg/kg every 21 days. Twelve patients were ALK positive and five were ALK negative. After treatment with brentuximab vedotin, nine patients then received either autologous or allogeneic transplant.[36][Level of evidence B4]
Sources: 36 · Level of evidence B4
Brentuximab vedotin has been evaluated in children with recurrent or refractory anaplastic large cell lymphoma. › In a phase II study, 17 patients (median age, 11 years) were treated with brentuximab vedotin at a dose of 1.8 mg/kg every 21 days. Twelve patients were ALK positive and five were ALK negative. After treatment with brentuximab vedotin, nine patients then received either autologous or allogeneic transplant.[36][Level of evidence B4]
The overall response rate was 53% (9 of 17 patients), with a complete response rate of 41% (7 of 17 patients), a partial response rate of 12% (2 of 17 patients), a stable disease rate of 29% (5 of 17 patients), and a progressive disease rate of 18% (3 of 17 patients).
The median EFS was 4.8 months.
The OS rate was 93.3% at 24 months.
Evidence (autologous vs. allogeneic HSCT):
A retrospective study of patients with relapsed or refractory anaplastic large cell lymphoma who received BFM-type first-line therapy, reinduction chemotherapy, followed by autologous HSCT reported the following:[30][Level of evidence B4]
Sources: 30 · Level of evidence B4
A retrospective study of patients with relapsed or refractory anaplastic large cell lymphoma who received BFM-type first-line therapy, reinduction chemotherapy, followed by autologous HSCT reported the following:[30][Level of evidence B4]
A 5-year EFS rate of 59% and an OS rate of 77%. However, the outcomes were poor for patients with bone marrow or CNS involvement, relapse during first-line therapy, or CD3-positive anaplastic large cell lymphoma. These patients may benefit from allogeneic transplant.
In a European prospective study of patients with relapsed or refractory anaplastic large cell lymphoma, primary refractory patients received aggressive multiagent chemotherapy and underwent allogeneic HSCT. Relapsed patients with CD3-positive disease received less-intense multiagent chemotherapy and allogeneic HSCT (recommended therapy) or autologous HSCT if no donors were available. Relapsed patients with CD3-negative disease (<1 year from diagnosis) received less-aggressive chemotherapy and autologous HSCT. Relapsed patients with CD3-negative disease (>1 year from diagnosis) received single-agent vinblastine for 2 years.[31] The study demonstrated the following results:
Sources: 31
In a European prospective study of patients with relapsed or refractory anaplastic large cell lymphoma, primary refractory patients received aggressive multiagent chemotherapy and underwent allogeneic HSCT. Relapsed patients with CD3-positive disease received less-intense multiagent chemotherapy and allogeneic HSCT (recommended therapy) or autologous HSCT if no donors were available. Relapsed patients with CD3-negative disease (<1 year from diagnosis) received less-aggressive chemotherapy and autologous HSCT. Relapsed patients with CD3-negative disease (>1 year from diagnosis) received single-agent vinblastine for 2 years.[31] The study demonstrated the following results:
For the entire cohort, the 5-year EFS rate was approximately 50%, and the OS rate was 77%.
For patients with refractory disease or early relapse, reinduction with multiagent chemotherapy followed by allogeneic HSCT achieved the best results (i.e., long-term EFS rate, 65%).
Patients who received autologous HSCT fared much worse (i.e., long-term EFS rate, 25%).
Patients who had a late relapse (>1 year from diagnosis) were treated with vinblastine for 2 years and achieved a 5-year EFS rate of 81%.
Treatment Options Under Clinical Evaluation for Anaplastic Large Cell Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Treatment options for lymphoproliferative disease associated with primary immunodeficiency
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for lymphoproliferative disease associated with primary immunodeficiency include the following:
Chemotherapy with or without rituximab.
Allogeneic hematopoietic stem cell transplant (HSCT).
Patients with primary immunodeficiency can achieve complete and durable remissions with standard chemotherapy regimens for NHL, although toxicity is increased.[2]; [5][Level of evidence C1] Recurrences in these patients are common and may not represent the same clonal disease.[6] Immunologic correction through allogeneic HSCT is often required to prevent recurrences.
Sources: 2 · 5 · Level of evidence C1 · 6
Treatment options for NHL associated with DNA repair defect syndromes
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Patients with DNA repair defects are particularly difficult to treat.[7,8] Overall survival (OS) rates at 5 and 10 years are poor, at 40% to 60%.[5,9]
Treatment options for NHL associated with DNA repair defect syndromes include the following:
Chemotherapy.
Chemotherapy.
Cytotoxic agents produce much more toxicity and greatly increase the risk of subsequent neoplasms in these patients. One review reported that dose reduction of chemotherapeutic drugs was effective and reduced toxic effects, but did not prevent subsequent neoplasms (10-year incidence rate, 25%).[9]
Sources: 9
Treatment options for HIV-associated NHL
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for HIV-associated NHL include the following:
Chemotherapy with or without rituximab.
In the era of highly active antiretroviral therapy, children with HIV and NHL are treated with standard chemotherapy regimens for NHL. However, the prevention (using prophylaxis) and early detection of infection is warranted.[1,13,14] Although the number of pediatric patients with HIV-associated NHL is too small to perform meaningful clinical trials, studies of adult patients support the addition of rituximab to standard treatment regimens.[15] Treatment of recurrent disease is based on histology using standard approaches.
Treatment options for PTLD
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for PTLD include the following:
For localized resectable disease, surgical resection and, if possible, reduction of immunosuppressive therapy.
Rituximab therapy alone.[22]
Sources: 22
Standard or slightly modified lymphoma-specific chemotherapy regimens for the specific histology, with or without rituximab for B-cell PTLD.[23-26]
For EBV-positive B-cell PTLD, low-dose chemotherapy with or without rituximab.[19]; [27][Level of evidence C2]
Sources: 19 · 27 · Level of evidence C2
First-line therapy for patients with PTLD is to reduce immunosuppressive therapy as much as possible.[27,28] However, this may not be possible because of the increased risk of organ rejection or graft-versus-host disease (GVHD).
Rituximab, an anti-CD20 antibody, has been used in the posttransplant setting. Rituximab as a single agent to treat PTLD after organ transplant has demonstrated efficacy in adult patients, but data are lacking in pediatric patients.
Evidence (rituximab):
A study of 144 children and adults who developed post-HSCT PTLD reported the following:[22][Level of evidence C1]
Sources: 22 · Level of evidence C1
A study of 144 children and adults who developed post-HSCT PTLD reported the following:[22][Level of evidence C1]
Approximately 70% of the patients who received rituximab survived.
Survival was also associated with reduction of immunosuppression.
Older age, extranodal disease, and acute GVHD were predictors of poor outcome.
For more information, see the Polymorphic Posttransplant Lymphoproliferative Disorder section in Aggressive B-Cell Non-Hodgkin Lymphoma Treatment.
Sources: Polymorphic Posttransplant Lymphoproliferative Disorder
Low-intensity chemotherapy has been effective in patients with EBV-positive, CD20-positive B-lineage PTLD.[19,29] An event-free survival (EFS) rate of 67% was demonstrated in a Children's Oncology Group study using rituximab plus cyclophosphamide and prednisone in children with PTLD after solid organ transplant in whom immune suppression was reduced.[19][Level of evidence B4]
Sources: 19 · 29 · 19 · Level of evidence B4
Some studies suggest that modified conventional lymphoma therapy is effective for patients who have PTLD with MYC translocations and Burkitt lymphoma histology.[24,25][Level of evidence C2] A multicenter retrospective review summarized the treatments and outcomes of 35 patients with PTLD-BL. Fluorescence in situ hybridization (FISH) detected the MYC translocation in 95% of cases. Treatments ranged from rituximab only to FAB/LMB therapy. The 3-year EFS and OS rates for all patients were 66.2% and 88.0%, respectively. The most commonly used therapy was a low-dose chemotherapy approach that is similar to the COG regimen (cyclophosphamide, prednisone, and rituximab [CPR]; n = 13). Using this approach, the EFS rate was 52.7%, and the OS rate was 84.6%.[26]
Sources: 24 · 25 · Level of evidence C2 · 26
Patients with T-cell or Hodgkin-like PTLD are usually treated with standard lymphoma-specific chemotherapy regimens.[30-33]
Antirejection therapy is usually decreased or discontinued when chemotherapy is given to avoid excessive toxicity. There are no data to guide the re-initiation of immunosuppressive therapy after chemotherapy treatment. There is little evidence of benefit for chemotherapy after HSCT.
Adoptive immunotherapy with either donor lymphocytes or ex vivo–generated EBV-specific cytotoxic T lymphocytes (EBV-CTLs) has been effective in treating patients with PTLD after blood or bone marrow transplant.[34,35] To make this approach more broadly applicable, banks of off-the-shelf, third-party, allogeneic EBV-CTLs derived from healthy donors have been developed.[36,37] EBV-CTLs were evaluated in 46 patients with PTLD that had either progressed during rituximab treatment, not fully responded to rituximab treatment, or had recurred after a previous response. The following results were observed:[38]
The lymphomas were monomorphic diffuse large B-cell lymphomas in 24 of 33 patients who underwent HSCT and in 8 of 13 patients who underwent solid organ transplants.
EBV-CTLs were selected for having at least one HLA allele shared between the donor EBV-CTLs and the lymphoma.
The objective response rate after one cycle of EBV-CTLs was 39% (9 complete responses [CRs] and 9 partial responses [PRs] among 46 patients). With additional cycles of therapy, 29 of 45 evaluable patients (64%) achieved CRs or sustained PRs.
Three of five recipients with progressive disease after their first cycle of EBV-CTLs achieved CRs or durable PRs after receiving EBV-CTLs from a different donor.
Of 11 patients with CNS involvement, 5 achieved CRs and 4 achieved durable PRs.
Factors associated with favorable response included previous treatment with rituximab only (i.e., no prior chemotherapy or radiation therapy), absence of extranodal disease, and more extensive in vivo expansion of the EBV-CTLs.
Treatment options under clinical evaluation for PTLD
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT03394365 (Tabelecleucel for Solid Organ or Allogeneic HSCT Participants With EBV-Positive PTLD After Failure of Rituximab or Rituximab and Chemotherapy [ALLELE]): The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of EBV-positive PTLD in the setting of: (1) solid organ transplant after failure of rituximab and rituximab plus chemotherapy; or (2) allogeneic HSCT after failure of rituximab.
Sources: NCT03394365
Immunodeficiency Associated With Acute Lymphoblastic Leukemia (ALL) Therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
An international collaboration identified 95 cases of lymphoid neoplasms after the diagnosis of ALL.[39] Of these cases, 52 were characteristic of EBV-associated lymphoproliferative disease in the setting of immunodeficiency. These 52 cases were analyzed, along with 14 additional cases identified from the literature (n = 66). All cases occurred in the maintenance phase or within 6 months of completing maintenance (median, 14 months into maintenance therapy). Treatment strategies varied, but two-thirds of the patients were event-free survivors at 5 years.
Sources: 39
Treatment options for pediatric-type follicular lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Pediatric-type follicular lymphoma is rare in children, with only case reports and small case series to guide therapy. The outcomes of patients with pediatric-type follicular lymphoma are excellent, with an event-free survival (EFS) rate of about 95%.[6,8-11,13] Unlike in adult follicular lymphoma, the clinical course in pediatric patients is not dominated by relapses.[6,8,11,12]
Treatment options for pediatric-type follicular lymphoma include the following:
Surgery only.
Multiagent chemotherapy with or without rituximab.
Studies suggest that for children with stage I disease who had a complete resection, a watch-and-wait approach without chemotherapy may be indicated. Patients with higher-stage disease also have a favorable outcome with low-intensity and intermediate-intensity chemotherapy, with an EFS rate of 94% and an overall survival (OS) rate of 100% (2-year median follow-up).[2,6,9,10] Although the number of pediatric patients with pediatric follicular-type lymphoma is too small to perform meaningful clinical trials, studies of adult patients with follicular lymphoma support the addition of rituximab to standard treatment regimens.
For patients with BCL2-rearranged tumors, treatment similar to that of adult patients with follicular lymphoma is administered.
For more information, see the Follicular Lymphoma (Grades 1–3a) section in Indolent B-Cell Non-Hodgkin Lymphoma Treatment.
Sources: Follicular Lymphoma (Grades 1–3a)
Treatment options for marginal zone lymphoma (including MALT lymphoma)
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for marginal zone lymphoma (including MALT lymphoma) include the following:
Surgery only.
Radiation therapy.
Rituximab with or without chemotherapy.
Antibiotic therapy, for MALT lymphoma.
Most pediatric patients with marginal zone lymphomas require no more than local therapy involving curative surgery and/or radiation therapy.[22,24] Treatment of patients with MALT lymphoma of the gastric mucosa may also include antibiotic therapy, which is considered standard treatment in adults. A series of five patients with H. pylori-associated MALT lymphoma received triple therapy with amoxicillin, nitroimidazole or a macrolide, and a proton pump inhibitor for 14 days. All patients achieved H. pylori eradication and had complete resolution of histological findings at the last follow-up.[25]
Evidence (treatment of marginal zone lymphoma):
In the largest retrospective study of pediatric patients (aged 18 years or younger) with marginal zone lymphoma (N = 66), the following was reported:[26][Level of evidence C1]
Sources: 26 · Level of evidence C1
In the largest retrospective study of pediatric patients (aged 18 years or younger) with marginal zone lymphoma (N = 66), the following was reported:[26][Level of evidence C1]
The overall 5-year EFS rate was 70%.
The OS rate was 98%.
Patients primarily fell into the following two WHO-defined groups:
In the largest retrospective study of pediatric patients (aged 18 years or younger) with marginal zone lymphoma (N = 66), the following was reported:[26][Level of evidence C1] › Patients primarily fell into the following two WHO-defined groups:
Nodal (32%): Nearly all patients were male, with localized primary tumors in the head and neck. The treatment for all patients was resection (complete or incomplete) followed by observation. The EFS rate was 94%, and the OS rate was 100%.
Extranodal (67%): 57% of patients were male, and 27% of patients had a preexisting condition, which was immune compromising in most patients. The treatment options included chemotherapy, radiation, rituximab, resection, and observation. The EFS rate was 64%, and the OS rate was 97%. The only two deaths resulted from treatment-related complications of HSCT. Both patients had an underlying immunodeficiency. Of note, 9 of 12 patients with extranodal marginal zone lymphoma who were managed with resection only remained in a first continuous complete remission with no further therapy. The other 3 patients who relapsed had their disease successfully salvaged.
Although the number of pediatric patients with MALT lymphoma is too small to perform meaningful clinical trials, studies of adult patients support the use of rituximab with or without chemotherapy. For more information, see the Marginal Zone Lymphoma section in Indolent B-Cell Non-Hodgkin Lymphoma Treatment.
Sources: Marginal Zone Lymphoma
Intralesional interferon-alpha for conjunctival MALT lymphoma has been studied in trials.[27]
Sources: 27
Treatment options for primary CNS lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for primary CNS lymphoma include the following:
Chemotherapy and rituximab (for mature B-cell disease).
Radiation therapy.
Therapy with high-dose intravenous methotrexate and cytosine arabinoside is the most successful, and intrathecal chemotherapy may be needed only when malignant cells are present in the cerebrospinal fluid.[32]
Sources: 32
There are case reports describing the administration of repeated doses of intraventricular rituximab in patients with refractory primary CNS lymphoma, with excellent results reported.[33,34] This apparently good outcome needs to be confirmed, and similar results have not been observed in adults. It is generally believed that rituximab does not cross the blood-brain barrier.
Among patients who have a partial response (PR) to induction therapy, and particularly those who are not eligible for transplant, reduced-dose whole-brain radiation therapy with a boost to residual disease may be a viable treatment approach that merits further investigation.[35,36]
For more information about treatment options for non–AIDS-related primary CNS lymphoma, see Primary CNS Lymphoma Treatment.
Sources: Primary CNS Lymphoma Treatment
Treatment options for peripheral T-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Optimal therapy for peripheral T-cell lymphoma is unclear for both pediatric and adult patients.
Treatment options for peripheral T-cell lymphoma include the following:
Chemotherapy.
Radiation therapy.
Allogeneic or autologous HSCT.[47]
Sources: 47
There have been four retrospective analyses of treatment and outcome for pediatric patients with peripheral T-cell lymphoma.
Evidence (treatment of peripheral T-cell lymphoma):
The United Kingdom Children's Cancer Study Group (UKCCSG) examined 25 children diagnosed with peripheral T-cell lymphoma over a 20-year period and reported the following:[37]
Sources: 37
The United Kingdom Children's Cancer Study Group (UKCCSG) examined 25 children diagnosed with peripheral T-cell lymphoma over a 20-year period and reported the following:[37]
A 5-year survival rate of approximately 50%.
The UKCCSG also observed that the use of acute lymphoblastic leukemia–like therapy, instead of NHL therapy, produced a superior outcome.
The COG reported on 20 patients older than 8 years who were treated on Pediatric Oncology Group NHL trials.[38]
Sources: 38
The COG reported on 20 patients older than 8 years who were treated on Pediatric Oncology Group NHL trials.[38]
Eight of ten patients with low-stage disease achieved long-term disease-free survival, compared with only four of ten patients with high-stage disease.
In a study of Japanese children with peripheral T-cell lymphoma (N = 21), treatment included chemotherapy (n = 18), radiation therapy (n = 2), and autologous (n = 2) and allogeneic (n = 9) HSCT.[48]
Sources: 48
In a study of Japanese children with peripheral T-cell lymphoma (N = 21), treatment included chemotherapy (n = 18), radiation therapy (n = 2), and autologous (n = 2) and allogeneic (n = 9) HSCT.[48]
The 5-year OS rate was 85.2%.
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
Sources: 40 · Level of evidence C2
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
Patients with peripheral T-cell lymphoma, NOS (n = 18), most with advanced disease (stage III [n = 10] and stage IV [n = 5]), were usually treated with anaplastic large cell lymphoma protocols and had a 10-year EFS rate of 61%.
Patients with NK/T-cell lymphoma (n = 9) fared poorly, with a 10-year EFS rate of 17%.
This series also included five patients with hepatosplenic T-cell lymphoma and five patients with subcutaneous panniculitis-like T-cell lymphoma.
For more information about the treatment of adults, see Peripheral T-Cell Non-Hodgkin Lymphoma Treatment.
Treatment options for cutaneous T-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Because of the rarity of cutaneous T-cell lymphoma, no standard treatments have been established. Management and treatment of patients with cutaneous T-cell lymphoma should be individualized and, in some cases, watchful waiting may be appropriate. Treatment may only be necessary if hemophagocytic syndrome develops.[58]
Sources: 58
There is no standard treatment regimen for SPTCL. Spontaneous remissions have been observed, particularly in younger children. Older children, however, may have a course of disease that is complicated by hemophagocytic syndrome. First-line treatment consists of either chemotherapy or immunomodulatory drugs. Chemotherapy was the mainstay of treatment before 2019. Immunomodulatory therapy or observational follow-up became the mainstay of treatment after this time. Immunomodulatory agents include steroids combined with cyclosporine A or ruxolitinib. In a series of 18 patients, the CR rate was 71.4% for patients treated with these immunomodulatory agents.[55][Level of evidence C3]
Sources: 55 · Level of evidence C3
An oral retinoid (bexarotene) has been reported to be active against SPTCL in a series of 15 patients from three institutions.[59] In a series of 11 pediatric patients, aggressive polychemotherapy was used in all patients. Nine of 11 patients sustained clinical remission, with a median follow-up of 3.5 years.[56] Additional treatment options include high-dose steroids, bexarotene, denileukin diftitox, multiagent chemotherapy, and HSCT.[53,58-63]
Primary cutaneous anaplastic large cell lymphoma usually does not express ALK and may be treated successfully with surgical resection and/or local radiation therapy without systemic chemotherapy.[64] There are reports of surgery alone also being curative for patients with ALK-positive cutaneous anaplastic large cell lymphoma, but extensive staging and vigilant follow-up is required.[65,66]
Treatment options for mycosis fungoides
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Mycosis fungoides in pediatric patients may respond to various therapies, including topical steroids, retinoids, radiation therapy, or phototherapy (e.g., narrowband UVB treatment [NBUVB]), but remission may not be durable.[72-75] In a retrospective series of 71 pediatric patients with mycosis fungoides, the overall response rate (CR + partial remission) was 88%. However, CR was achieved in only 40% of patients initially.[69][Level of evidence C3]
Sources: 72 · 75 · 69 · Level of evidence C3
NBUVB monotherapy was the most commonly administered treatment to pediatric patients with early-stage nonfolliculotropic mycosis fungoides. The CR rate was 63% for these patients. In contrast, pediatric patients with early-stage folliculotropic mycosis fungoides had a CR rate of 29% with NBUVB (P = .04).
UVA-based phototherapy, such as systemic psoralen plus UVA (PUVA), bath PUVA, or UVA combined with NBUVB, were the most commonly administered treatments to patients with folliculotropic mycosis fungoides, with CR rates of 60% versus 81% for patients with nonfolliculotropic mycosis fungoides (P = .17).
During a mean follow-up of 9.2 years, four of the patients with early-stage disease (6%) experienced progression of their disease stage. Two of these patients (both with folliculotropic mycosis fungoides) progressed to advanced-stage disease.
Treatment options for lymphomatoid papulosis
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
No treatment regimen has proven effective in altering the lymphoid papulosis disease course or preventing associated neoplasms.
A wait-and-see strategy is often chosen and considered an appropriate first-line approach.[77]
Sources: 77
Patients with a few lesions can be treated with moderate-to-high potency topical or intralesional corticosteroids.[77]
Sources: 77
Phototherapy (NBUVB) can be used for widespread disease.[77]
Sources: 77
Low-dose methotrexate has been used for those with extensive or scarring lesions. Aggressive chemotherapy is not recommended.[77]
Sources: 77
Other agents such as brentuximab vedotin have been used. In a series of 12 adult patients (youngest age, 27 years) with refractory lymphomatoid papulosis, all patients responded, including 7 who had CRs.[78] One patient with relapsed disease was re-treated and remained in a PR for more than 23 months.[78] In a phase II study of brentuximab vedotin that included nine adult patients with lymphomatoid papulosis, there were five CRs and four PRs.[79]
Certain factors affect prognosis (chance of recovery) and treatment options.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
If your child has been diagnosed with non-Hodgkin lymphoma, you likely have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis.
The prognosis depends on:
the type of lymphoma
where the cancer is in the body at diagnosis
the stage of the cancer
whether there are certain changes in the chromosomes
the type of initial treatment
whether the lymphoma responded to initial treatment
your child's age and general health
No two people are alike, and responses to treatment can vary greatly. Your child's cancer care team is in the best position to talk with you about your child's prognosis.
Sometimes childhood non-Hodgkin lymphoma does not respond to treatment or recurs (comes back) after treatment.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Refractory non-Hodgkin lymphoma is cancer that does not respond to initial treatment.
Sources: Refractory
Recurrent non-Hodgkin lymphoma is cancer that has come back after treatment. It may come back in the lymph system or in other parts of the body.
Sources: Recurrent
Treatment Option Overview
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Key Points
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
There are different types of treatment for children with non-Hodgkin lymphoma.
Children with non-Hodgkin lymphoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.
The following types of treatment may be used:
The following types of treatment may be used:
Surgery
Chemotherapy
Radiation therapy
Stem cell transplant
Targeted therapy
Other drug therapy
Phototherapy
Watchful waiting
Immunotherapy
Treatment for childhood non-Hodgkin lymphoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Follow-up care may be needed.
There are different types of treatment for children with non-Hodgkin lymphoma.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the cancer is located, the type of non-Hodgkin lymphoma, whether the cancer is newly diagnosed or has come back, and your child's age and overall health.
Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and possible side effects. It will be helpful for you to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Children with non-Hodgkin lymphoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of non-Hodgkin lymphoma. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and also specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
radiation oncologist
Sources: radiation oncologist
pediatric hematologist
Sources: pediatric hematologist
pediatric surgeon
Sources: pediatric surgeon
pediatric nurse specialist
Sources: pediatric nurse specialist
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
social worker
Sources: social worker
The following types of treatment may be used:
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Surgery
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Surgery may be done to remove as much of the tumor as possible for some types of childhood non-Hodgkin lymphoma. After the doctor removes all the cancer that can be seen at the time of surgery, patients may be given chemotherapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · adjuvant therapy
Chemotherapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment.
Chemotherapy for childhood non-Hodgkin lymphoma is taken by mouth or injected into a vein. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body. Chemotherapy for childhood non-Hodgkin lymphoma is also placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen. When given this way, the drugs mainly affect cancer cells in those areas.
Sources: injected · cerebrospinal fluid · intrathecal chemotherapy · organ · cavity · abdomen
Intrathecal chemotherapy may be used to treat childhood non-Hodgkin lymphoma that has spread, or may spread, to the brain. When used to lessen the chance cancer will spread to the brain, it is called CNS prophylaxis. Intrathecal chemotherapy is given in addition to chemotherapy by mouth or vein. Higher than usual doses of chemotherapy may also be used as CNS prophylaxis.
Sources: brain · CNS prophylaxis · doses
Chemotherapy drugs used alone or in combination to treat non-Hodgkin lymphoma in children include:
asparaginase
Sources: asparaginase
carboplatin
Sources: carboplatin
cyclophosphamide
Sources: cyclophosphamide
cytarabine
Sources: cytarabine
dexamethasone (steroid)
Sources: dexamethasone
doxorubicin
Sources: doxorubicin
etoposide
Sources: etoposide
idarubicin
Sources: idarubicin
ifosfamide
Sources: ifosfamide
methotrexate
Sources: methotrexate
prednisone (steroid)
Sources: prednisone
vinblastine
Sources: vinblastine
vincristine
Sources: vincristine
Other chemotherapy drugs not listed here may also be used.
The way the chemotherapy is given depends on the type and stage of the cancer being treated.
Sources: stage
Learn more about Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Radiation therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. External radiation therapy may be used to treat childhood non-Hodgkin lymphoma that has spread, or may spread, to the brain and spinal cord. It may also be used to treat cutaneous T-cell lymphoma (mycosis fungoides).
Sources: Radiation therapy · spinal cord · cutaneous T-cell lymphoma · mycosis fungoides
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Stem cell transplant
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. This treatment destroys healthy cells, including blood-forming cells. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells. The donor stem cells may also find and kill any cancer cells left in the body.
Sources: blood · Stem cell transplant · bone marrow · donor · infusion
Targeted therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. Types of targeted therapy used to treat non-Hodgkin lymphoma in children include:
brentuximab vedotin
Sources: brentuximab vedotin
crizotinib
Sources: crizotinib
denileukin diftitox
Sources: denileukin diftitox
pembrolizumab
Sources: pembrolizumab
rituximab
Sources: rituximab
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Other drug therapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Retinoids are drugs related to vitamin A. Retinoid therapy with bexarotene is used to treat several types of cutaneous T-cell lymphoma.
Sources: Retinoids · vitamin A · bexarotene
Steroids are hormones made naturally in the body. They can also be made in a laboratory and used as drugs. Steroid therapy that is applied to the skin is used to treat cutaneous T-cell lymphoma. Dexamethasone and prednisone are steroids used with other drugs to treat certain types of lymphoma.
Sources: Steroids · hormones · Dexamethasone · prednisone
Antibiotics are drugs used to treat infections and cancer caused by bacteria or other microorganisms. Antibiotics have been used to treat mucosa-associated lymphoid tissue (MALT) lymphoma. Treatment with antibiotic therapy has been mostly studied in adults.
Sources: Antibiotics · infections · bacteria · microorganisms · mucosa-associated lymphoid tissue (MALT) lymphoma
Phototherapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Phototherapy uses a drug and a certain type of laser light to kill cancer cells. A drug that is not active until it is exposed to light is injected into a vein. The drug collects more in cancer cells than in normal cells. For cancer in the skin, laser light is shined onto the skin and the drug becomes active and kills the cancer cells. Phototherapy is used in the treatment of cutaneous T-cell lymphoma.
Sources: Phototherapy · laser
Watchful waiting
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · monitoring · condition · signs · symptoms
Immunotherapy
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Immunotherapy helps a person's immune system fight cancer. Types of immunotherapy include:
CAR T-cell therapy changes the patient's T cells (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of Burkitt lymphoma and diffuse large B-cell lymphoma that has not responded to treatment or has recurred (come back).
Sources: CAR T-cell therapy · T cells · receptors · chimeric antigen receptor
Cyclosporine A is used in combination with steroids to treat subcutaneous panniculitic T-cell lymphoma.
Sources: Cyclosporine A
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Treatment for childhood non-Hodgkin lymphoma may cause side effects.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:
physical problems, including problems with the heart, bones, and fertility
Sources: fertility
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer), such as brain tumors, acute myeloid leukemia, and myelodysplastic syndrome
Sources: second cancers · brain tumors · acute myeloid leukemia · myelodysplastic syndrome
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.
Patients may want to think about taking part in a clinical trial.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Follow-up care may be needed.
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).
Treatment Options for Childhood Non-Hodgkin Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of newly diagnosed Burkitt lymphoma may include:
Sources: diagnosed · Burkitt lymphoma
surgery to remove as much of the tumor as possible, followed by combination chemotherapy
Sources: combination chemotherapy
combination chemotherapy with or without targeted therapy (rituximab)
Sources: rituximab
Treatment of recurrent or refractory Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of recurrent or refractory Burkitt lymphoma may include:
Sources: recurrent · refractory · Burkitt lymphoma
combination chemotherapy with or without targeted therapy (rituximab)
Sources: combination chemotherapy · rituximab
targeted therapy (rituximab), combination chemotherapy, and dexamethasone
Sources: dexamethasone
high-dose chemotherapy with stem cell transplant with the patient's own cells or cells from a donor
Sources: high-dose chemotherapy · stem cell transplant · donor
CAR T-cell therapy
Sources: CAR T-cell therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of newly diagnosed diffuse large B-cell lymphoma may include:
Sources: diagnosed · diffuse large B-cell lymphoma
surgery to remove as much of the tumor as possible, followed by combination chemotherapy
Sources: combination chemotherapy
combination chemotherapy with or without targeted therapy (rituximab)
Sources: rituximab
Treatment of recurrent or refractory diffuse large B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of recurrent or refractory diffuse large B-cell lymphoma may include:
Sources: recurrent · refractory · diffuse large B-cell lymphoma
combination chemotherapy with or without targeted therapy (rituximab)
Sources: combination chemotherapy · rituximab
targeted therapy (rituximab), combination chemotherapy, and dexamethasone
Sources: dexamethasone
stem cell transplant with the patient's own cells or cells from a donor
Sources: stem cell transplant · donor
CAR T-cell therapy
Sources: CAR T-cell therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Primary Mediastinal B-cell Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of primary mediastinal B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of newly diagnosed primary mediastinal B-cell lymphoma may include combination chemotherapy, prednisone, targeted therapy (rituximab), and sometimes radiation therapy.
Sources: diagnosed · primary mediastinal B-cell lymphoma
Treatment of recurrent or refractory primary mediastinal B-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of recurrent or refractory primary mediastinal B-cell lymphoma may include targeted therapy (pembrolizumab).
Sources: recurrent · refractory · primary mediastinal B-cell lymphoma · pembrolizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Lymphoblastic Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of lymphoblastic lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Lymphoblastic lymphoma may be classified as the same disease as acute lymphoblastic leukemia (ALL). Treatment of lymphoblastic lymphoma may include:
Sources: Lymphoblastic lymphoma · acute lymphoblastic leukemia
combination chemotherapy
Sources: combination chemotherapy
CNS prophylaxis with radiation therapy or intrathecal chemotherapy may also be given to keep cancer from spreading to the brain or spinal cord
Sources: CNS prophylaxis · radiation therapy · cancer · brain · spinal cord
Treatment of recurrent or refractory lymphoblastic lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of recurrent or refractory lymphoblastic lymphoma may include:
Sources: recurrent · refractory · lymphoblastic lymphoma
chemotherapy
Sources: chemotherapy
stem cell transplant with cells from a donor
Sources: stem cell transplant · donor
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Anaplastic Large Cell Lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of anaplastic large cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of anaplastic large cell lymphoma may include:
Sources: anaplastic large cell lymphoma
surgery followed by combination chemotherapy
Sources: combination chemotherapy
combination chemotherapy with or without prednisone
Sources: prednisone
intrathecal and combination chemotherapy, for patients with cancer in the brain or spinal cord
Sources: intrathecal · brain · spinal cord
Treatment of recurrent or refractory anaplastic large cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of recurrent or refractory anaplastic large cell lymphoma may include:
Sources: recurrent · refractory · anaplastic large cell lymphoma
chemotherapy
targeted therapy (brentuximab vedotin or crizotinib)
Sources: brentuximab vedotin · crizotinib
chemotherapy followed by a stem cell transplant with the patient's own cells or cells from a donor
Sources: stem cell transplant · donor
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Lymphoproliferative Disease Associated With Immunodeficiency in Children
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of lymphoproliferative disease associated with primary immunodeficiency
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of lymphoproliferative disease in children and adolescents with weakened immune systems may include:
Sources: lymphoproliferative disease · adolescents · immune systems
chemotherapy with or without targeted therapy (rituximab)
Sources: rituximab
stem cell transplant with cells from a donor may be used to treat the primary immunodeficiency and to decrease the risk of cancer coming back
Sources: stem cell transplant · donor · immunodeficiency
Treatment of non-Hodgkin lymphoma associated with DNA repair defect syndromes
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of non-Hodgkin lymphoma associated with DNA repair defect syndromes in children may include chemotherapy.
Sources: non-Hodgkin lymphoma · DNA repair defect syndromes
Treatment of HIV-associated non-Hodgkin lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment with highly active antiretroviral therapy or HAART (a combination of antiretroviral drugs) lowers the risk of non-Hodgkin lymphoma in patients infected with HIV.
Sources: highly active antiretroviral therapy · antiretroviral drugs · non-Hodgkin lymphoma · infected · HIV
Treatment of HIV-related non-Hodgkin lymphoma (NHL) in children may include chemotherapy with or without targeted therapy (rituximab).
Sources: rituximab
Treatment of post-transplant lymphoproliferative disease
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of post-transplant lymphoproliferative disease may include:
Surgery to remove the tumor. If possible, lower doses of immunosuppressive drugs after a stem cell or organ transplant may be given.
Sources: doses · immunosuppressive drugs · stem cell · organ · transplant
Targeted therapy (rituximab).
Sources: rituximab
Chemotherapy with or without targeted therapy (rituximab).
Rare NHL Occurring in Children
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment of pediatric-type follicular lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of follicular lymphoma in children may include:
Sources: follicular lymphoma
surgery
combination chemotherapy with or without targeted therapy (rituximab)
Sources: combination chemotherapy · rituximab
For children whose cancer has certain changes in the genes, treatment is similar to that given to adults with follicular lymphoma. For information about the treatment of follicular lymphoma in adults, visit Non-Hodgkin Lymphoma.
Sources: genes · Non-Hodgkin Lymphoma
Treatment of marginal zone lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of marginal zone lymphoma (including mucosa-associated lymphoid tissue [MALT] lymphoma) in children may include:
Sources: marginal zone lymphoma · mucosa-associated lymphoid tissue [MALT] lymphoma
surgery
radiation therapy
targeted therapy (rituximab) with or without chemotherapy
Sources: rituximab
antibiotic therapy, for MALT lymphoma
Sources: antibiotic · therapy
Treatment of primary CNS lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of primary CNS lymphoma in children may include chemotherapy and targeted therapy (rituximab).
Sources: primary CNS lymphoma
Treatment of peripheral T-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of peripheral T-cell lymphoma in children may include:
Sources: peripheral T-cell lymphoma
chemotherapy
radiation therapy
stem cell transplant with the patient's own cells or cells from a donor
Sources: stem cell transplant · donor
Triangle